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ABSTRACT

Hormonally-triggered regulatory hierarchies play a major role in organismal
development. Disruption of a single member of such a hierarchy can lead to irregular
development and disease. Therefore, knowledge of the members involved and the mechanisms
controlling signaling through such pathways is of great importance in understanding how
resulting developmental defects occur.
Type II transmembrane serine proteases (TTSPs) make up a family of cell surfaceassociated proteases that play important roles in the development and homeostasis of a number
of mammalian tissues. Aberrant expression of TTSPs is linked to several human disorders,
including deafness, heart and respiratory disease and cancer. However, the mechanism by which
these proteases function remains unknown.
The ecdysone-responsive Stubble TTSP of Drosophila serves as a good model in which
to study the functional mechanism of the TTSP family. The Stubble protease interacts with the
intracellular Rho1 (RhoA) pathway to control epithelial development in imaginal discs. The
Rho1 signaling pathway regulates cellular behavior via control of gene expression and actin
cytoskeletal dynamics. However, the mechanism by which the Stubble protease interacts with the
Rho1 pathway to control epithelial development, in particular leg imaginal disc morphogenesis,
has yet to be elucidated.
The Stubble protein consists of several conserved domains. One approach to a better
understanding of the mechanism of action of Stubble in regulating Rho1 signaling is to define
which of the conserved domains within the protease are required for proper function. Sequence
iii

analysis of twelve recessive Stubble mutant alleles has revealed that the proteolytic domain is
essential for proper function. Alleles containing mutations which disrupt regions of the protease
domain necessary for protease activation or substrate binding, as well as those with deletions or
truncations that remove some portion of the proteolytic domain, result in defective epithelial
development in vivo. In contrast, mutations in other regions of the Stubble protein, including the
disulfide-knotted and cytoplasmic domains, were not observed.
Another important step for defining the connection between Stubble and Rho1 signaling
is to identify a Stubble target that acts as an upstream regulator of the Rho1 pathway. We
performed a genetic screen in which 97 of the 147 Drosophila non-olfactory and non-gustatory
G-protein-coupled receptors (GPCRs), a family of proteins that has been shown to be proteaseactivated and to activate Rho1 signaling, were tested for interactions with a mutant allele of
Stubble. We found 4 genomic regions uncovering a total of 7 GPCRs that interact genetically
when in heterozygous combination with a Stubble mutant. Further analysis of these genes is
necessary to determine if any of these GPCRs is targeted by Stubble during activation of the
Rho1 pathway.
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CHAPTER ONE: INTRODUCTION

Studies of human disease have typically been undertaken in cell culture and mammalian
model systems. Although these systems are more amenable to genetic manipulation than humans
themselves, they have significant limitations. Studies in cell culture suffer from the disadvantage
that cells are usually not observed in a natural context with cell-cell adhesion contacts
maintained. The extent to which the absence of cell adhesion influences normal cellular behavior
is unknown. Mammalian model systems permit in vivo manipulation of genes but can be very
costly to perform.
Over the past 10 years, Drosophila has emerged as an excellent model in which to study
human development and disease. Genetic studies can be performed in vivo and at a fraction of
the cost of mammalian model systems. Major advantages of Drosophila are the sophisticated
genetic tools that have been developed over the past 100 years, limited genetic redundancy
allowing gene function to be readily determined, and the discovery of a high degree of
conservation of gene function with humans. For example, studies in Drosophila of biochemical
signaling pathways highly conserved between Drosophila and vertebrates has greatly increased
understanding of the major signaling pathways central to regulation of metazoan development
and homeostasis (Wassarman et al., 1995; Cadigan and Nusse, 1997; Greenwald, 1998; Johnson
and Scott, 1998). Drosophila models have also been developed toward identifying the
mechanisms of a number of human neuropathologies, such as Alzheimer’s, Parkinson’s and
Huntington’s diseases (Jackson et al, 1998; Warrick et al, 1998; Bilen and Bonini, 2005). In
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addition, many human genes known to play direct roles in cancers have highly conserved
orthologs in Drosophila (Hariharan and Bilder, 2006).
Here I focus on a class of poorly characterized transmembrane serine proteases associated
with a variety of human pathologies. I hypothesize that studies of these proteases in a Drosophila
model will be important in establishing a direct link between the action of these proteases and
human disease.

Vertebrate type II transmembrane serine proteases and pathology
Upon sequencing of vertebrate genomes, a surprising number of genes belonging to
previously identified but sparsely populated protease families have been described. One of these
families, the mammalian type II transmembrane serine protease (TTSP) family, has rapidly
grown into a family of 21 membrane–associated proteases with known roles in development and
homeostasis in a variety of mammalian tissues.
TTSPs have an atypical mode of insertion into the membrane (intracellular N-terminus
and extracellular C-terminus; Singer, 1990). All members of this protease family have a similar
structure, consisting of a short intracellular domain, an extracellular stem region and a highly
conserved catalytic serine protease domain of the chymotrypsin (S1) fold subfamily (Hooper et
al., 2001). Within the extracellular stem region, various conserved domains may be found (Szabo
and Bugge, 2008). TTSPs have been divided into four subfamilies based on a phylogenetic
analysis of the serine protease domain as well as domain structure of the extracellular stem
region and chromosomal location of their genes (Figure 1; Szabo et al., 2003). The largest is the
human airway trypsin (HAT)/differentially expressed in squamous cell carcinoma (DESC)
2

subfamily, followed by the hepsin/TMPRSS/enteropeptidase subfamily, the matriptase
subfamily, and the corin subfamily.
The catalytic activity of TTSPs is dependent on the presence of three residues in the
proteolytic domain, histidine, aspartate, and serine, which make up the catalytic triad. Enzymatic
activity is further modulated by the structural organization of the substrate binding pocket which
is responsible for conferring substrate specificity. All TTSPs contain a highly conserved
activation motif preceding the catalytic domain, suggesting that they are synthesized as single
chain zymogens and must be activated by proteolytic cleavage after a lysine or arginine residue.
Upon activation, the catalytic domain remains covalently linked to the membrane-bound stem
region, and thus to the cell surface, by a conserved disulfide bond (Hooper et al., 2001). The
specific mechanism of activation of individual TTSPs is unknown. However, all members of the
TTSP family are trypsin-like, containing Gly216 and Gly226 (chymotrysinogen numbering) at
the top of the S1 pocket, or primary specificity site, and Asp189 at the bottom of the pocket.
TTSPs should, therefore, exhibit strong preference for substrates containing an Arg or Lys
residue in the P1 position (Perona and Craik, 1997), and indeed, all tested members of the TTSP
family exhibit this Arg/Lys specificity (Takeuchi et al., 2000; Velasco et al., 2002; Hobson et al.,
2004; Szabo et al., 2005). These data suggest that activation may occur upon cleavage by other
TTSPs or by autoactivation.
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Figure 1. Predicted domain structures of mammalian type II transmembrane serine proteases.
Numbers indicate the position of each domain in the amino acid sequence of the zymogen.
Figure and legend taken in modified form from Szabo and Bugge, 2008.
4

The TTSP family is of particular clinical interest because misexpression of several of its
members has been linked to a number of pathologies. At least 15 different mutations in the
TMPRSS3 gene are associated with non-syndromic congenital and childhood onset autosomal
recessive deafness in human patients (Ben-Yosef et al., 2001; Masmoudi et al., 2001; Scott et al.,
2001; Wattenhofer et al., 2001; Ahmed et al., 2004; Wattenhofer et al., 2005; Elbracht et al.,
2007; Guipponi et al., 2008). Interestingly, mice deficient for another TTSP, hepsin, also display
hearing loss and developmental defects in the inner ear (Guipponi et al., 2007), suggesting that
several TTSPs may play a cooperative role in normal inner ear development.
Several TTSP family members have been implicated in cancer. Hepsin is consistently
misexpressed and the most upregulated gene in prostate cancer, expressed solely on the surface
of prostate tumor cells (Dhanasekaran et al., 2001; Luo et al., 2001; Magee et al., 2001; Stamey
et al., 2001; Welsh et al., 2001). Upregulation of hepsin in vivo causes disruption and
disorganization of the prostate basement membrane and leads to metastasis and cancer
progression in mice (Klezovitch et al., 2004). Misexpression of another TTSP, TMPRSS2, is also
associated with prostate cancer progression. One study identified two genetic abnormalities in a
subset of prostate cancer patients. Approximately 38% of patients showed a duplication of the
TMPRSS2 gene, while a single individual with aggressive prostate cancer showed a 7-bp deletion
which resulted in a frameshift mutation and truncation of the protein after incorporation of only
one catalytic triad residue (Vaarala et al., 2001). Other studies have shown that a majority of
prostate cancer patients exhibit chromosomal rearrangements leading to fusion of the TMPRSS2
gene with the ERG, ETV1, and ETV4 genes which encode oncogenic transcription factors of the
ETS family (Soller et al., 2006; Tomlins et al., 2005, 2006). TMPRSS2 is an androgen-responsive
5

gene (Lin et al., 1999; Jacquinet et al., 2001), thus fusions with TMPRSS2 result in androgendependent regulation of ETS transcription factors and subsequent overexpression in androgensensitive prostate tissue.
Misexpression of matriptase, was first noted in breast carcinoma (Shi et al., 1993; Lin et
al, 1997) and has since been described in benign and malignant epithelial tumors of diverse
origins (reviewed in Bugge et al., 2007). Matriptase is expressed in a variety of embryonic and
adult tissues, but its expression is limited to the epithelial compartments of these tissues
(Takeuchi et al., 1999; Oberst et al., 2003; List et al., 2006; Netzel-Arnett et al., 2006; Fan et al.,
2007; Szabo et al., 2007). Tight regulation of matriptase activity in these tissues is essential for
normal epithelial development. As shown by List et al. (2005), even a modest overexpression in
the epidermis of transgenic mice leads to induction of spontaneous squamous cell carcinomas. In
addition to an association with epithelial cancers, misexpression of matriptase is linked to
additional pathologies involving the skin and hair, further strengthening the necessity for proper
regulation of matriptase activity during development. Matriptase-deficient mice develop to term
but die shortly after birth due to severe dehydration resulting from greatly impaired epidermal
barrier function. These mice also display absence of whiskers, hair follicle hypoplasia, and
accelerated apoptosis of immature T cells in the thymus (List et al., 2002). Recently, BaselVanagaite et al. (2007) reported a single amino acid substitution (G827R) in a highly conserved
glycine hinge residue in the protease domain of human ST-14, which encodes matriptase. This
mutation is found in patients with ichthyosis with hyptrichosis (ARIH) syndrome, a rare
autosomal recessive form of skin disease. Patients present with mild to moderate ichthyosis,
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indicative of impaired barrier function, and follicular hypoplasia characterized by sparse, fragile,
brittle, dry and lusterless hair that shows slow growth.
Finally, the corin subfamily of TTSPs has been linked to heart development and
cardiovascular disease. A minor allele of corin, a TTSP confined to the cardiac myocytes of the
atrium and ventricle (Yan et al., 1999; Hooper et al., 2000), was recently associated with a
human population with high systolic blood pressure and an increased risk for chronic
hypertension (Dries et al., 2005).
Because misexpression of TTSPs is associated with a variety of human pathologies,
understanding the mechanism of action of this class of proteins is crucial for disease treatment
and prevention. One approach to understanding the mechanism of action of TTSPs is to
determine the relationship between the conserved domains contained within the proteases and in
vivo function of the protease. It has been established that a protease domain with an intact
catalytic triad is necessary for activation and subsequent catalytic activity (Oberst et al. 2003;
Hammonds and Fristrom, 2006). The functions of the various conserved domains found in
TTSPs are generally not well understood; however, for several proteases, a requirement for these
domains has been demonstrated. For example, matriptase is a multi-domain TTSP containing a
SEA (sperm protein, enterokinase, and agrin) domain, two tandem CUB (C1r/s, Uegf, and bone
morphogenic protein-1) domains, and four tandem LDLRA (low density lipoprotein receptor
class A) domains within the extracellular region (see Figure 1). A series of mutations made in
each of these domains indicates that intact function of each domain type is essential for
matriptase activation (Oberst et al., 2003). Upon mutation of a putative glycosylation site in the
first CUB domain, a dramatic reduction of protease-inhibitor complex formation and
7

immunoreactivity with M69 mAb, an antibody which recognizes only the two-chain activated
matriptase, was observed. This indicates that glycosylation of the first CUB domain is necessary
for protease activation. The LDLRA domain contains a “calcium cage,” an octahedral
arrangement of a Ca2+ atom, which is involved in the binding of this domain to substrates. Point
mutation of critical residues of the calcium cage previously shown to be necessary for substrate
binding (Esser et al., 1988) was made in each of the four LDLRA domains of matriptase. For
each domain separately and all four domains simultaneously, this mutation inhibited proteaseinhibitor complex formation and M69 immunoreactivity, suggesting that all of the LDLRA
domains are essential for activation. Interestingly, efficient matriptase activation was observed
following deletion of all four LDLRA domains. This suggests that the LDLRA domains may
serve dual functions as binding domains for activators of matriptase and as autoinhibitory
domains when no activators are present. Finally, the SEA domain contains a consensus cleavage
site which serves as a target for proteolytic processing. Cleavage at this site converts matriptase
into a smaller form lacking the N-terminal and transmembrane regions. When N-terminal
proteolytic processing is inhibited via mutation of the cleavage site, no protease activation occurs
in in vitro assays, indicating that N-terminal cleavage is necessary for enzyme activation (Oberst
et al., 2003).
TMPRSS3, another multi-domain protease, consists of a single LDLRA domain followed
by a single SRCR (scavenger receptor cysteine rich) domain in its extracellular stem region (see
Figure 1). Two missense mutations have been identified in the LDLRA domain. One of these
mutations affects a highly conserved residue and is believed to impair the calcium binding site of
the domain (Wattenhofer et al., 2002). The second mutation affects the last residue of the
8

LDLRA domain, which is potentially involved in binding with extracellular molecules (BenYosef et al., 2001). These mutations result in almost complete loss of protease activity in vitro
and are associated with hearing loss (Guipponi et al., 2002). In addition, two missense mutations
in highly conserved residues of the TMPRSS3 SRCR domain have been identified in patients
with congenital and childhood onset hearing loss (Wattenhofer et al., 2002; Hutchin et al., 2005).
One of these SRCR mutations also results in almost complete loss of protease activity in in vitro
assays (Guipponi et al., 2002).
It is important to note that in most cases the linkage between mutant TTSP alleles and
human disease has not been directly established. Thus, an assay system that could determine the
activity of mutant TTSPs in vivo, and provide functional genetic rescue capability would be of
great benefit to this field. In the section on future studies (see discussion) I describe how the
Drosophila model system used in these studies could be utilized to this end.

The Drosophila Stubble TTSP as a model to study the mechanism of action of the TTSP family
The only non-vertebrate TTSPs that have been characterized are the Drosophila Stubble
and corin proteases and their orthologues in other arthropod species (Beaton et al., 1988; Appel
et al., 1993; Irving et al., 2001; Zou et al., 2006). The Stubble locus encodes a typical member of
TTSP family and is required for normal leg, wing and bristle morphogenesis. Based on sequence
analysis of the protease domain, the Stubble protease shows greatest sequence similarity to the
matriptase subfamily in vertebrates. The Stubble protease ends in a trypsin-like serine protease
domain of 244 amino acids and contains a 35-residue disulfide knotted domain, or clip domain,
9

specific to arthropods, within its extracellular stem (Figure 2; Appel et al., 1993). The
cytoplasmic domain is 58 amino acids in length and contains one putative protein kinase C
(PKC) phosphorylation site, one putative cAMP phosphorylation site, and 3 putative Nmyristoylation sites. The PKC phosphorylation consensus pattern, SRR, where serine is the
phosphorylation site, is found between residues 49 and 51 in the Stubble protein. The cAMP
phosphorylation site has the consensus pattern RRsT and is found between residues 14 and 17.
The consensus patterns for N-myristoylation present in Stubble are GSrgSG at residues 38-43,
GSggAA at residues 41-46 and GGaaAR at residues 43-48. The N-terminus of the Stubble
protein is hydrophilic, preceding a hydrophobic transmembrane anchor sequence. The
transmembrane domain is flanked by charged regions (positive intracellular and negative
extracellular) that are required for correct orientation of the protein in the membrane (see figure
2; Singer, 1990).
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Figure 2. Structure of the active Stubble protease.
The Stubble protease is composed of four major regions: the intracellular (cytoplasmic) domain,
the transmembrane domain, the stem region, and the proteolytic domain. A disulfide knotted
domain, specific to arthropods, is found within the stem region.

The disulfide knotted domain, the only conserved domain contained within the
extracellular stem of the Stubble protease, is connected to the protease domain by a linking
sequence of 329 amino acids, substantially longer than the 23 to 101 amino acid residues found
in most other clip domain-containing proteins (Jiang and Kanost, 1999). Disulfide knotted
domains are held together by a series of three disulfide bonds which result in a compactly folded
structure which can be schematically drawn in the shape of a paper clip, hence the alternative
11

designation of clip domain (Iwanaga et al., 1998). In addition to disulfide bridges formed within
the clip and proteolytic domains an additional disulfide bond links the proteolytic and stem
regions in the activated protease ensuring that the protease remains tethered to the membrane
upon activation cleavage (Figure 3; Muta et al., 1990, 1993). Several functions have been
proposed for disulfide knotted domains. They may function as mediators of interactions between
proteases and their activators or substrates. It is also possible that disulfide knotted domains act
as inhibitors of the protease domains to which they are linked. It is known that certain proteases,
such as the cysteine protease cathepsin L and convertases of the serine protease subtilisin family,
can be inhibited by their own propeptides (Carmona et al., 1996; Boudreault et al., 1998).
Supporting this idea is the fact that disulfide knotted domains are small structures stabilized by
disulfide bonds, common features of many canonical serine-type protease inhibitors (Bode and
Huber, 1992). However, mutational analysis of the cysteine residues in the disulfide knotted
domain of snake, a serine protease involved in dorsoventral patterning in Drosophila, argues
against an autoinhibitory role (Smith et al., 1993). Alteration of five of the six individual cysteine
residues to serine resulted in a failure of the protease to phenotypically rescue snake-deficient
embryos. The remaining cysteine residue exhibited some phenotypic rescue upon alteration to
serine, but activity was greatly reduced from wild type. Simultaneous alteration of cysteine pairs
involved in disulfide bridge formation as well as deletion of the entire disulfide knotted domain
also resulted in a failure to rescue snake-deficient animals. These data suggest that conserved
disruption or removal of the disulfide knotted domain leads to a loss of snake activity. The
opposite effect, constitutive activation, would be expected if the disulfide knotted domain acted
as an inhibitor of the snake protease.
12

Figure 3. Structural organization of disulfide knotted (clip) domain proteases.
Clip domain proteases contain a linker region of variable length connecting the clip domain to a
carboxy-terminal serine protease domain. A disulfide bond between conserved cysteine residues
in the stem and proteolytic domains ensures that these domains remain covalently attached
following activation of the zymogen. Figure and legend taken from Jiang and Kanost, 2000.

In this study I have chosen to use the Drosophila Stubble protease as a model to study
TTSP action in epithelia. The Stubble locus is transcriptionally induced in response to the steroid
hormone 20-hydroxyecdysone, a major mediator of morphogenetic events (Appel et al., 1993).
Upon induction by ecdysone, the Stubble protein is localized to the apical cell membrane of
developing leg and wing imaginal discs where it functions to control epithelial morphogenesis
(von Kalm et al., 1995; Hammonds and Fristrom 2006). Studies in our laboratory have shown
that in leg imaginal discs Stubble acts upstream of the monomeric GTPase Rho1, a major
regulator of the actin cytoskeleton, and that this interaction occurs via an outside-in signaling
13

mechanism (Bayer et al., 2003). Thus, further studies of the mechanism underlying the
interaction between Stubble and Rho1 are likely to improve our understanding of vertebrate
TTSP action in development, homoestasis and disease.
In the following sections, I will describe in more detail the process of leg imaginal disc
morphogenesis, the involvement of the Stubble protease in this process and the interaction
between Stubble and Rho1 signaling in control of epithelial morphogenesis.
Leg imaginal disc development
In Drosophila, the steroid hormone 20-hydroxyecdysone (ecdysone) is necessary to
mediate a major portion of the developmental process, metamorphosis. During metamorphosis,
adult structures such as legs, eyes and wings arise from small epithelial organs called imaginal
discs. Imaginal discs arise from invaginations of the embryonic epidermis (Cohen, 1993). During
larval development, imaginal discs grow by mitotic division. Proliferation of the discs proceeds
until just prior to metamorphosis, at which point the leg disc, for example, is simply a sac-like
epithelial structure connected to the interior surface of the epidermis by a stalk where the original
invagination occurred. This sac is composed of a thick folded columnar epithelium on one side,
resembling a Danish pastry, and a flat squamous epithelium on the other. (Fristrom and Fristrom,
1993). At the end of larval development, a sharp increase in the titer of ecdysone occurs. This
increase inhibits cell proliferation and triggers morphogenesis of the imaginal discs (Figure 4). It
is during the subsequent 12-hour prepupal period of development that the leg and wing discs, for
example, give rise to structures which resemble the adult appendages, and then evert to the
outside of the body wall. The prepupal development of leg imaginal discs is depicted in Figure 5.
14

Following stimulation by the metamorphic pulse of hormone, leg discs elongate and evert to the
outside of the animal. Elongation of the presumptive leg is driven by changes in apical cell shape
leading to unfolding of the disc and shaping of the epithelium into a tube-like structure.
Contraction of the actin-myosin contractile belt is the primary force underlying apical cell shape
changes in elongating leg discs (von Kalm et al., 1995). When actin-myosin contraction is misregulated, apical cell shape changes are abnormal resulting in a malformed leg and wing
phenotype, exemplified by legs that are shortened, thickened and twisted compared to normal
legs, and wings that are crumpled and frequently blistered (Figure 6).

Tissue-specific responses

S
Imaginal
Discs

98

to ecdysone

120/0

Proliferation

Morphogenesis

12

Hours

Differentiation

Figure 4. Fluctuations in ecdysone titer trigger imaginal disc morphogenesis at the onset of
metamorphosis.
Proliferation of the leg imaginal discs occurs throughout larval development. The sharp rise in
ecdysone titer (red line) occurring at 120 hours post egg laying inhibits further proliferation and
triggers the elongation of the disc and subsequent eversion. Time 120h represents the end of
larval development and the beginning of the 12 hour prepupal period and metamorphosis. At this
point, the time line resets to 0h. A major phase of prepupal leg morphogenesis occurs during the
first 6 hours of the prepupal period. Further morphogenesis and differentiation occur during the
following 4-day pupal period.
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Figure 5. Cell shape changes in leg imaginal discs during elongation.
(a-d) Confocal micrographs of prepupal discs stained with phalloidin to visualize filamentous
actin. (a) A leg at the beginning of the prepupal period. (b) A leg after 6 hours of prepupal
development. (c and d) Apical view in cross-section indicated by arrows in a and b. Note the
change in apical cell shape from anisometric to isometric in the elongating disc. (e) A schematic
of cell shape changes that occur during elongation of the leg disc. (f) Apical view of a leg disc
stained for Drosophila non-muscle myosin indicating the location of the actin-myosin contractile
belt. (Photographs a-d from Condic et al., 1990; e-f from von Kalm et al., 1995).

Figure 6. The malformed phenotype.
Defects in genes controlling cell shape changes result in malformed legs and wings (right panels)
compared to wild-type (left panels) (from Bayer et al., 2003). Note that the mutant legs are
shortened, thickened and twisted compared to normal legs. Wings are crumpled and frequently
display blisters (separation of the wing epithelial bilayer).
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Stubble function in normal development
The Stubble protein is expressed at the apical surface of leg imaginal disc cells, and
multiple mutations in the Stubble locus have been identified which lead to the malformed leg
phenotype. The malformed phenotype observed in Stubble mutant animals is caused by a failure
of cell shape change in leg disc epithelia (Condic et al., 1991). The Stubble protease has also
been linked to the Rho1 signaling pathway and control of actin cytoskeletal dynamics (Bayer et
al., 2003; see below). Thus, a major role for the Stubble protease in leg disc development may be
control of cell shape changes through regulation of the actin cytoskeleton.
Mutations in Stubble interact genetically with mutations in several members of the Rho1
signaling pathway in leg imaginal discs. Rho1 pathway members showing moderate to strong
interaction with Stubble include DRhoGEF2, Rho1, Rho kinase (drok), zipper (non-muscle
myosin II heavy chain), cofilin phosphatase, and myosin phosphatase (shown in red in Figure 7).
In addition to genetic interaction data, leg malformation associated with overexpression of
Stubble during leg morphogenesis can be suppressed by reducing Rho1 gene dosage (Bayer et
al., 2003). These data suggest that Stubble acts upstream of the Rho1 pathway and may be
required for temporal and spatial activation of Rho1 signaling during leg disc elongation.
The Rho family of small guanosine triphosphates (GTPases) plays an important role in
the regulation of epithelial morphogenesis. Rho1, Rac, and Cdc42 are three well-studied
members of this family that act to regulate a variety of epithelial processes including but not
limited to cell growth, cell division, cell adhesion and apical-basal and planar cell polarity.
Regulation occurs by control of actin cytoskeletal dynamics and nuclear gene transcription
through nucleation, polymerization, and depolymerization of actin filaments, and by control of
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the actin-myosin contractile apparatus. Rho1, Rac, and Cdc42 regulate actin dynamics in part
through involvement in intracellular signaling complexes in vertebrate and invertebrate epithelia
(reviewed in Van Aelst and Symons, 2002).

Stubble

ERM

?
RhoGEF

RhoGDI

RhoGDP
(inactive)

RhoGTP (active)
RhoGAP
Diaphanous

Rho Kinase
(drok)
Myosin Light ChainKinase
Myosin
Phosphatase
(mbs)

LIM Kinase
Cofilin
Cofilin
Phosphatase
(ssh)
F-Actin Filamentation

Myosin Regulatory
Light Chain (sqh)

Profilin

Myosin II Heavy Chain (zipper)
DSRF/Transcription
Actin-myosin Contraction
Cell Shape Change

Figure 7. Rho1 regulation of actin contraction and filamentation. See text for details.
Drosophila orthologs of the vertebrate Rho kinase (drok), myosin regulatory light chain (sqh;
Spaghetti Squash), non-muscle myosin II heavy chain (zipper), myosin phosphatase (mbs;
myosin binding subunit), and cofilin phosphatase (ssh; slingshot) are indicated. Mutations in
Rho1 pathway genes that interact genetically with Stubble mutations in leg imaginal discs are
indicated in red.
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Studies in vertebrate systems have provided a model for Rho1 signaling which leads to
contraction of the actin-myosin contractile belt in epithelia (Figure 7). While only one Rho
protein, Rho1, is present in Drosophila, three equivalent proteins, RhoA, RhoB and RhoC are
present in vertebrates. Functionally, Rho1 is believed to be most similar to the vertebrate RhoA,
though at the amino acid level, percent identity between Rho1 and human RhoA, B and C is
identical (Hariharan et al., 1995). Rho1-specific guanine nucleotide exchange factors (RhoGEFs)
are activated by extracellular signals that trigger a relocation of the GEF to the plasma membrane
where it forms a complex with its target Rho1 GTPase (Zheng et al., 1996). Activated RhoGEF
promotes cycling of the inactive form of Rho1 (GDP-bound) to the active form (GTP-bound).
ERM (ezrin, radixin, and moesin) family proteins on the plasma membrane inhibit the
association of guanine dissociation inhibitors (GDIs) with the inactive Rho1, thus reinforcing
Rho1 activation through a positive feedback loop (Tsukita et al., 1997; Matsui et al., 1998). ERM
proteins may also be involved in a negative feedback loop regulating Rho1 activity, thus fine
tuning the rate of cycling of Rho1 between the GDP- and GTP-bound states (Speck et al., 2003).
Activated Rho1 then stimulates the downstream effectors Rho kinase and Diaphanous. Activated
Rho kinase stimulates at least two different substrates, splitting the pathway into a myosindependent branch and a Lim kinase-dependent branch. In the myosin-dependent branch, Rho
kinase phosphorylates and thus activates myosin regulatory light chain (Sqh) (Amano et al.,
1996) and inhibits myosin light chain phosphatase (Kimura et al., 1996). Activation of the
myosin regulatory light chain leads to activation of myosin II heavy chain (Zipper) and
contraction of the actin-myosin belt. In the Lim kinase-dependent branch of the pathway, Rho
kinase activates Lim kinase, which inhibits the turnover of F-actin by cofilin, leading to
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stabilization and accumulation of F-actin and subsequent cell shape change (Maekawa et al.,
1999). Activated Diaphanous must cooperate functionally with Lim kinase to induce
accumulation of F-actin (Geneste, Copeland and Treisman, 2002). While Rho kinase-Lim kinase
signaling inhibits F-actin turnover, Rho1 promotes F-actin assembly by binding to and thus
relieving autoinhibition of Diaphanous, which, in conjunction with profilin, nucleates actin
filaments resulting in formation of unbranched F-actin filaments (Watanabe et al., 1999; Pruyne
et al., 2002; Sagot et al., 2002).
Rho signaling and disease
Studies have recently shown Rho family proteins to be involved in tumorigenesis. The
mechanisms by which these proteins are involved in cancer progression have not been defined
but the links existing between Rho proteins and cancer are considerable. Misexpression of
members of the RhoA signaling pathway in vertebrates has been associated with a variety of
cancers of epithelial origin (reviewed in Benitah et al., 2004). Given that TTSPs are thought to
be involved in disease progression via interaction with intracellular signaling pathways and that
the RhoA pathway in vertebrates has been linked to disease, the interaction of the Stubble
protease with the Rho1 signaling pathway in Drosophila serves as an excellent model in which
to study the mechanistic role of TTSPs in disease.

G protein-coupled receptors are a potential link between Stubble proteolytic activity and Rho1
signaling
The genetic data presented above strongly implicate Stubble in Rho1 signaling.
Interactions have been detected between mutations in the Stubble gene and DRhoGEF2, Rho1,
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drok, cofilin phosphatase, myosin phosphatase, zipper and DSRF (shown in red in Figure 7).
Also, a reduction in the gene dosage of Rho1 suppresses the severe malformed leg phenotype
induced by overexpression of Stubble (Bayer et al., 2003). As a result of these studies, it has
been proposed that the Stubble protease operates through an “outside-in” signaling mechanism
during leg development to either act in parallel with or directly regulate Rho1 signaling, though
the mechanism by which this occurs is unknown.
In an attempt to better understand the mechanism by which Stubble acts, a genome-wide
screen for genes that interact with Stubble to control leg development was initiated (von Kalm et
al., unpublished). Using a deletion strategy, 80Mb (85%) of the Drosophila autosomal genome
was screened for chromosomal intervals containing genes whose products interact with Stubble
during epithelial morphogenesis to regulate cell morphology. Twelve intervals containing
interacting gene products were identified. Six of these intervals uncover heterotrimeric guanine
nucleotide-binding protein (G protein)-coupled receptors (GPCRs), a family of proteins through
which Stubble could potentially link to intracellular Rho1-mediated signaling events.
In addition to Stubble, four vertebrate type II transmembrane serine proteases also appear
to operate through an “outside-in” signaling mechanism. Enteropeptidase, HAT (human airway
trypsin), Matriptase/MT-SP1, and TMPRSS2 have all been linked to intracellular signaling
events which involve PAR (protease-activated receptor)-2 (Takeuchi et al., 2000; Cottrell et al.,
2004; Chokki et al., 2005; Wilson et al., 2005). PARs are a subset of G protein-coupled receptors
that are activated by proteolytic cleavage of the receptor, creating a tethered ligand that cannot
diffuse away, rather than by simple ligand occupancy (Vu et al., 1991). Proteolytic activation of
PARs is mediated by the serine protease family. PARs are expressed in a number of normal cell
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types as well as in tumor cells and invasive cell lines and are found in carcinoma specimens.
PAR-2, specifically, is expressed in a number of cell types including vascular endothelial cells,
myocytes, fibroblasts, immune cells, neurons, glial cells and a variety of epithelial cells. The
physiological role of the PARs in different cell types includes, but is not limited to, control of
homeostasis, inflammation, pain and healing, and proliferation (MacFarlane et al., 2001).
G protein-coupled receptors, which are able to activate heterotrimeric G proteins, are
known to be major upstream regulators of Rho signaling. G proteins couple activated GPCRs to
the initiation of intracellular signaling responses by acting on downstream effector molecules.
Several Rho-specific GEFs have been shown to act as effectors of various G protein α subunits
in mammalian systems, thus coupling activation of Rho signaling with G protein signaling
events. A number of distinct G protein α subunits have been identified and are divided into four
families based on amino acid sequence similarity and function: Gs, Gi, Gq and G12 (Wilkie et al.,
1992). PDZ-RhoGEF, p115 RhoGEF and leukemia-associated Rho guanine nucleotide exchange
factor (LARG) interact with the G12 family subunits Gα12 and Gα13 through their regulator of G
protein signaling (RGS) domains (Hart et al., 1998; Kozasa et al., 1998; Fukuhara et al., 1999,
2000). LARG has also been shown to cooperate with activated Gαq/11, as well as Gα12/13, to
stimulate activation of RhoA, suggesting that LARG can also serve as an effector for Gq coupled
receptors (Booden et al, 2002; Vogt et al., 2003). More recently, p63RhoGEF was shown to
couple Gq/11- but not G12/13-coupled receptors to Rho signaling (Lutz et al., 2005, 2007). It was
further demonstrated that the p63RhoGEF-induced enhancement of RhoA activation occurred by
direct protein-protein interaction between the C-terminus of p63RhoGEF and active Gαq or Gα11.
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Aims of this study
Localization to the cell surface puts type II transmembrane serine proteases in an
excellent position to mediate signal transduction between intracellular signaling pathways and
the extracellular environment and to regulate cellular responses. Indeed, a number of TTSPs
have been shown to play important roles in the normal development of tissues and have been
associated with a variety of human diseases, including heart disease and cancer. To understand
the distinct roles that TTSPs play in tissue development and disease, it is necessary to define
their function on a mechanistic level. Two approaches to a better understanding of the
mechanism of action of TTSPs in regulating cellular response are to define which of the
conserved domains within the proteases are required for proper function and to identify TTSP
targets that could act as upstream regulators of intracellular signaling and response pathways.
Because the Stubble TTSP is known to play a role in epithelial morphogenesis through
interaction with the intracellular Rho1 signaling pathway, it serves as an excellent model in
which to study the mechanism of action of the TTSP family.
In an attempt to identify the essential conserved domains of the Stubble protein, I
sequenced twelve recessive mutant alleles of Stubble. Coding region mutations were identified in
nine of these alleles and all but one localize to the protease domain. The remaining mutation
localizes to the stem region and affects the amino acid residue directly preceding the disulfide
knotted domain. Mutations in other regions of the Stubble protein, including the disulfideknotted and cytoplasmic domains, were not observed. These data identify the protease domain as
essential for function but do not rule out the remaining domains as necessary functional
components.
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Because G protein-coupled receptors have been identified as TTSP targets and have also
been linked to the Rho1 pathway via activation of G protein α-subunits, I asked if GPCRs might
be targeted by Stubble to regulate Rho1 signaling. These experiments involved a genetic screen
of the non-gustatory and non-odorant GPCRs in the Drosophila genome for interactions with a
mutant Stubble allele. At present, 97 of the 147 total non-gustatory, non-odorant receptors have
been tested, and 4 genomic regions which interact genetically with the Stubble mutant have been
identified. These regions uncover a combined total of 8 GPCRs. Further analysis is necessary to
determine if any of these GPCRs are targeted by Stubble leading to activation of the Rho1
pathway.
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CHAPTER TWO: METHODS

Drosophila stocks
Drosophila sbd, Rho1, and zipper mutant alleles used in this study are described in Table
1. All sbdE(br) stocks were obtained from R. Ward (University of Kansas; Ward et al. 2003). All
deficiency stocks used in this study were obtained from the Bloomington Drosophila Stock
Center at Indiana University (Bloomington, IN). Transgenic stocks are described below. All
stocks were maintained at 25º on standard cornmeal/yeast/agar medium.

Genetic complementation analysis
To genetically test the activity of the sbd mutants, second-site noncomplementation
(SSNC) assays were performed by mating animals heterozygous for sbd mutations with animals
heterozygous for other mutant genes of interest. Leg malformation was scored in the doubly
heterozygous F1 progeny class (i.e., */+; sbd/+). Genotypes generated to test for dominant
interactions (i.e., Rho172O/+; sbd*/sbd1) were obtained by mating animals carrying sbd
mutations, e.g., sbd*/TM6B, Tb Hu e, to Rho172O/CyO-CR2, P{sevRas1.V12}FK1; sbd1/TM6B,
Tb Hu e animals. In each cross, 7-10 virgin females were mated with 5 males. All crosses were
set up in duplicate. Cultures were incubated at 25º for either 3 or 5 days followed by transfer of
adults to fresh medium. Subsequent cultures were incubated for 2 or 5 days, respectively, until a
total of 6 cultures per cross were generated.
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Table 1. Mutant alleles of stocks used in this study
Mutant Allele
sbdE(br)20
sbdE(br)48
sbdE(br)228
sbdE(br)448
sbdE(br)536
sbdE(br)623
sbdPNR11
sbdVE3
sbd1
sbd206
sbd46
sbd173
sbd241
sbd258
sbd266
sbd277
Df(3R)sbd105
Rho1J3.8
Rho1E3.10
Rho172O
Rho1k02107b
zipEbr

Mutagen
EMS
EMS
EMS
EMS
EMS
EMS
EMS
EMS
Spontaneous
EMS
EMS
EMS
EMS
EMS
EMS
EMS
X ray
EMS
EMS
P-element
insertion/excision
P-element insertion
EMS

Reference
Ward et al. (2003)
Ward et al. (2003)
Ward et al. (2003)
Ward et al. (2003)
Ward et al. (2003)
Ward et al. (2003)
Heitzler and Simpson (1991)
Heitzler and Simpson (1991)
Dobzhansky (1930)
Hecht (1989)
R. Ruggiero (unpublished data)
R. Ruggiero (unpublished data)
R. Ruggiero (unpublished data)
R. Ruggiero (unpublished data)
R. Ruggiero (unpublished data)
R. Ruggiero (unpublished data)
Beaton et al. (1988)
Halsell et al. (2000)
Halsell et al. (2000)
Strutt et al. (1997)
Magie et al. (1999)
Gotwals and Fristrom (1991); Gotwals (1992);
Halsell et al. (2000)

To screen for G-protein-coupled receptors (GPCRs) potentially involved in leg
morphogenesis, SSNC assays were performed by mating heterozygous Stubble mutant animals
(i.e., red Sb63be/TM6B, Tb Hu e) with heterozygous or homozygous animals carrying a
deficiency uncovering the GPCR, or a transposable element insertion or mutation in the GPCR.
Leg malformation was scored in the doubly heterozygous F1 progeny class (i.e., */+; Sb/+).
Secondary SSNC assays of mutants found to interact in the primary screen were conducted by
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mating animals carrying interacting mutations with animals heterozygous for other mutant alleles
of interest (i.e., Sb70, Rho1E3.10, Rho1J3.8, Np125A and Np2) and by mating heterozygous Stubble
mutant animals (i.e., red Sb63be/TM6B, Tb Hu e) with animals carrying deficiencies overlapping
the region uncovered by the original interacting deficiency. All crosses were set up in duplicate.
Cultures were incubated at 25º for 5 days followed by transfer of adults to fresh medium.
Subsequent cultures were incubated for 5 days, until a total of 6 cultures per cross were
generated.

Lethal-phase analysis of sbd mutant alleles
Embryonic lethality was assessed by collecting 0- to 2-hr embryos from sbd/TM6B,
P{w+, UbiGFP} stocks. Embryos were aged to 15 hours at 25ºC and dechorionated in 50%
bleach for 3 minutes. Homozygous sbd embryos were then selected based on absence of green
fluorescent protein (GFP) expression. Homozygous embryos were aged at 25ºC to 48 hours postegg laying, and dead embryos were counted. Embryonic lethality was calculated as (number of
dead embryos/total number of mutant embryos) x 100. Dependent on the number present, 34-100
sbd mutant embryos were assessed in each experiment, and each experiment was done in
triplicate. Larval lethality was determined by collecting homozygous mutant sbd first instar
larvae derived from sbd/TM6B, P{w+, UbiGFP} stocks on the basis of absence of GFP
expression. Mutant larvae were allowed to develop for 7-10 days at 25ºC, and pupae were
counted. Larval lethality was calculated as [(total number of mutant larvae – number of
pupae)/total number of mutant larvae] x 100. Dependent on the number of hatchers, up to 100
larvae were assessed in each experiment, and each experiment was done in triplicate. Pupal
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lethality was determined by allowing pupae from the larval lethality assay to eclose. Adults were
counted and pupal lethality was calculated as [(total number of pupae – number of adults)/total
number of pupae] x 100.

Genetic characterization of sbd alleles
To genetically characterize the sbd alleles, 150 virgin sbd105 e ca/TM6B, P{w+, UbiGFP}
females and 150 sbd*/TM6B, P{w+, UbiGFP} females were mated separately to 75 sbd*/TM6B,
P{w+, UbiGFP} males. 0-2 hour embryos were collected on grape plates and aged to 15-17 hours
at 25º, at which time they were dechorionated in 50% bleach for 3 minutes. Homozygous sbd*
and trans-heterozygous sbd105 e ca/sbd* mutant embryos were then selected based on absence of
green fluorescent protein (GFP) expression and placed on a fresh grape plate. Embryos were then
aged at 25º to 48 hours post-egg-laying, at which time dead embryos were counted and hatched
larvae were transferred to a fresh plate with a strip of thin yeast paste and stored at 25º in a
humid chamber. Every 24 hours, dead larvae were counted, larval progress was observed and
noted, and larvae were transferred to a fresh plate containing a strip of thin yeast paste. Upon
reaching the third instar stage, larvae were placed in a vial containing Drosophila medium and
aged at 25º for a period of time sufficient for pupariation and eclosion of any viable adults.
Development and lethal-phase of homozygous sbd* mutants was compared to that of sbd105 e
ca/sbd* mutant trans-heterozygotes. Any sbd* allele exhibiting an identical developmental
pattern and lethal-phase as trans-heterozygotes is considered to be a null allele.
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Sequence analysis of sbd mutant alleles
To identify mutations in sbd alleles, genomic DNA from mutant animals in homozygous
and various heterozygous conditions (Table 2) was isolated via phenol-chloroform extraction
followed by ethanol precipitation. Twenty adults were collected for each mutant genotype
analyzed and ground using a motorized pestle in a 1.5 mL microcentrifuge tube containing 200μl
homogenizing buffer (100mM NaCl, 200mM sucrose, 100mM Tris-Cl, pH 9.1, 50mM EDTA,
0.5% SDS). Upon homogenization, an additional 500μl homogenizing buffer was added and
used to rinse the pestle. Phenol-chloroform extraction was performed by adding 250μl phenol
and 250μl chloroform (chloroform:isoamyl alcohol 24:1) and vortexing for 30 seconds, followed
by centrifugation at 4º for 5 minutes at 14,000 rpm. After spinning, the aqueous phase was
removed and a second phenol-chloroform extraction was performed as above. 500μl of the final
aqueous phase was placed in a clean microcentrifuge tube and prepared by ethanol precipitation
with 50μl 3M NaAc (pH 4.8-5.2) and 1mL cold 100% ethanol. Samples were mixed and spun at
4º for 5 minutes at 14,000 rpm. After centrifugation, the supernatant was decanted and pellets
were dried in a vacuum aspirator for 15 minutes, followed by resuspension in 200μl TE. A
second ethanol precipitation was performed using 20μl 3M NaAc (pH 4.8-5.2) and 400μl cold
100% ethanol. Samples were mixed and centrifuged at 4º for 5 minutes at 14,000 rpm.
Supernatant was removed and pellets were washed with 400μl 70% ethanol and centrifuged at 4º
for 5 minutes at 14,000 rpm. Supernatant was carefully removed by pipetting, and pellets were
dried in a vacuum aspirator for 15 minutes, followed by resuspension in 25μl TE containing
2mg/mL RNase. For homozygous lethal genotypes, 50 homozygous first instar larvae derived
29

from sbd/TM6B, P{w+, UbiGFP} stocks were collected based on absence of GFP expression, and
DNA was prepared as described above.
The Stubble locus was divided into six regions (Figure 8) for amplification and sequence
analysis. A series of intron- and exon-specific primers (Table 3) was used to amplify each
region. Amplification of all regions was conducted using a reaction mix containing 1X reaction
buffer (10mM Tris-HCl, pH 8.3, 50mM KCl), 10µM 3’-primer, 10µM 5’-primer, 0.8mM dNTPs,
1.5mM MgCl2 and 1U/rxn Jump-Start Taq polymerase. Stock solutions of reaction buffer (10X),
MgCl2 (25mM) and Jump-Start Taq were obtained from Invitrogen (Carlsbad, CA). All reactions
were done in a 20μl volume in 0.5mL thin-walled tubes in the UNOII Biometra Thermocycler.
Thermal cycler settings used for amplification were the same for all primer pairs and are shown
in Table 4. Amplification products were run on 1.0% Low EEO agarose, excised and purified
using the QIAquick Gel Extraction kit (Qiagen, Valencia, CA). DNA concentrations were
estimated by running 5ul of the purified product on 1.5% Low EEO agarose and comparing band
intensity to the quantitative Hyperladder II (Bioline USA Inc., Taunton, MA). Purified
amplification products and primers were sent to the Nevada Genomics Center for sequencing
using the ABI BigDye Terminator Cycle Sequencing Ready Reaction Kit v3.1 and the ABI3730
DNA Analyzer. Mutations were verified by sequencing independent PCR products amplified
from genomic DNA samples originating from different sets of animals of the same mutant
genotypes. DNA sequence analysis was facilitated by the use of the Lasergene 6 DNA and
protein analysis software (DNASTAR, Inc., Madison, WI).
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Table 2. Genotype and regions of all individual mutant stocks used for sequence analysis
Sb Regions Amplified and Sequenced
2
3
4
5
6
46
x
x
x
x
x
sbd /TM6B, Tb Hu e
1118
46
x
x
w /+; iso2/+; iso3/sbd
x
x
x
x
x
x
sbd173/TM6B, Tb Hu e
173
173
x
x
sbd /sbd
x
x
x
x
x
x
sbd241/TM6B, Tb Hu e
1118
241
x
x
w /+; iso2/+; iso3/sbd
x
x
x
x
x
x
sbd258/TM6B, Tb Hu e
1118
258
x
x
x
w /+; iso2/+; iso3/sbd
266
x
x
x
x
x
x
sbd /TM6B, Tb Hu e
x
x
x
x
w1118/+; iso2/+; iso3/sbd266
x
x
x
x
x
x
sbd277/TM6B, Tb Hu e
x
x
w1118/+; iso2/+; iso3/sbd277
x
x
x
x
x
x
sbdE(br)20/TM6B, Tb Hu e
x
x
x
sbdE(br)20/sbdE(br)228
E(br)48
x
x
x
x
x
x
sbd
/TM6B, Tb Hu e
E(br)48
E(br)228
x
x
sbd
/sbd
x
x
x
x
x
x
sbdE(br)228/TM6B, Tb Hu e
E(br)448
x
x
x
x
sbd
/TM6B, Tb Hu e
x
x
x
sbdE(br)448/sbdE(br)228
E(br)536
x
x
x
x
x
x
sbd
/TM6B, Tb Hu e
x
x
x
sbdE(br)536/ sbdE(br)228
x
x
x
x
sbdE(br)623/TM6B, Tb Hu e
E(br)623
E(br)228
x
x
sbd
/sbd
x
x
sbdE(br)623/sbdE(br)623
1
1
x
x
x
x
x
x
sbd st ro e ca/ sbd st ro e ca
x
x
x
x
x
x
red sbd201e/TM6B, Tb Hu e
201
201
x
x
x
x
x
x
red sbd / red sbd
206
x
x
x
x
x
x
sbd ru cu e ca/ TM6B, Tb Hu e
206
206
x
x
sbd ru cu e ca/ sbd ru cu e ca
PNR11
x
x
x
x
x
x
st sbd
e/ TM6B, Tb Hu e
x
x
x
st sbdPNR11e/ st sbdPNR11e
VE3
x
x
x
x
x
x
st sbd e/ TM6B, Tb Hu e
x
x
x
st sbdVE3e/ st sbdVE3e
w1118/ w1118; iso2/iso2; iso3/iso3 (isoline)
x
x
x
x
x
x
1
1
x
x
x
x
x
x
br / br
Regions 1–6 refer to the six regions into which the Stubble genetic locus was split for sequencing
purposes (see Figure 8). A cross (x) denotes successful amplification and sequencing of the
specified region for the given genotype.
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Genotype

1
x

Region 4R
(11968924)
Region 2R
Region 4IR
(11967038)
(11968639)
Region 2F
(11966176)
Region 4IF
(11968602)
Region 4F
(11968247)

Region 6R
(11970995)
Region 6IR
(11970601)
Region 6IF
(11970427)

Region 6F
(11970002)

Exon

Region 5F
Region 1F
Region 3F
(11969238)
(11965421) (11967010)
Region 5IF
Region 1R Region 3IF
(11969576)
(11965703) (11967342)
Region 3IR
Region 5IR
(11967533)
(11969696)
Region 3R
Region 5R
(11967815)
(11970028)

Figure 8. Stubble genomic structure and locations of primers used to sequence mutant sbd alleles.
Sizes of introns and exons are shown to scale and indicated in kilobases. Exons are shown as black boxes with exon number
indicated below. Features from the cDNA (5’- and 3’-UTR, ATG translation start) are indicated above the exons in which they
are found. The protease domain is split between the last four exons. Each of the residues forming the catalytic triad (H, D, S) is
encoded in a separate exon, each indicated above the corresponding exon. The transmembrane domain (TMD), cysteineknotted domain (knot) and the first part of the stem are in exon 4. For sequencing purposes, the coding domain of the Stubble
locus was split into 6 regions. Forward (F) and reverse (R) primers for each region are indicated. Specific primer sequences are
shown in Table 3. Numbers given with the primers denote the molecular position of its 5’ end. Colored dashes within the
exons mark the positions of the internal primers in regions 3 (red), 4 (blue), 5 (green), and 6 (yellow). Figure and legend are
taken in modified form from Hammonds and Fristrom, 2006.
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Table 3. Primers used to amplify and sequence the coding region of the Stubble locus
Primer Name
5’ Sb Exon 1(1)
3’ Sb Exon 1(1)
5’ Sb Region 2
3’ Sb Region 2
5’ Sb Region 3
3’ Sb Region 3
Sb Region 3F seq
Sb Region 3R seq
5’ Sb Region 4
3’ Sb Region 4
Sb Region 4F seq
Sb Region 4R seq
5’ Sb Region 5
3’ Sb Region 5
Sb Region 5F seq
Sb Region 5R seq
5’ Sb Region 6
3’ Sb Region 6
Sb Region 6F seq
Sb Region 6R seq

Alternate
Name
Region 1F
Region 1R
Region 2F
Region 2R
Region 3F
Region 3R
Region 3IF
Region 3IR
Region 4F
Region 4R
Region 4IF
Region 4IR
Region 5F
Region 5R
Region 5IF
Region 5IR
Region 6F
Region 6R
Region 6IF
Region 6IR

Region
Amplified
1
1
2
2
3
3
3 (internal)
3 (internal)
4
4
4 (internal)
4 (internal)
5
5
5 (internal)
5 (internal)
6
6
6 (internal)
6 (internal)

Exon(s)
Amplified
3
3
4
4
5,6
5,6
5,6
5,6
7
7
7
7
8,9
8,9
8,9
8,9
10,11
10,11
10,11
10,11

5’ Molecular
Coordinate (3R)
11965421
11965703
11966176
11967038
11967010
11967815
11967342
11967533
11968247
11968924
11968602
11968639
11969238
11970028
11969576
11969696
11970002
11970995
11970427
11970601

33

Primer Sequence
(5’→3’)
CATTCTCGATGCCATTACAAACATA
AACTGGTAGCACACATCGCTGCCTCC
AAGTGCGCTTAATTAGTGGTGGACT
GATATATTATGCTATCTTTCAAGCCGCTT
AAGCGGCTTGAAAGATAGCATAATATATCT
GTTTGTTTCGCTTTCGACATCAAT
GATGCATTGTTAGCATGA
GCAAATTGACGATGCCGG
TTCTTAGTTAATGCAGATTTAGCGGC
CTAATAAGCTATCATCTTCAATGAGCAAGC
CTCCAGCTCGAGCACCTC
GAGTCTTGCTCGATGTGG
TCAATTTGTGAGGGAATTCGAGATACAGTT
TAATTGCAATCGCCCCATTTAGAACC
GATCCAGATCGAGCTAAT
GCTCTATGTAGGGCAGCT
TGGTTCTAAATGGGGCGATTGCAATTA
TATTGCTCTCGAGCTTTCGCATCGCTAT
CGGAGTCTGTACGAGAAT
TGAAGCTAACTACGCT

Table 4. Thermal cycling parameters for amplification of sbd alleles
Segment

Cycles

1
2

1
31

3
4

1
1

Temperature
94ºC
94ºC – Denaturation
55ºC – Annealing
72ºC – Extension
72ºC
25ºC

Time
3 minutes
1 minute
1 minute
1 minute
15 minutes
30 minutes

Site-directed mutagenesis
Site-directed mutagenesis was performed on a full-length Stubble cDNA including 838
nucleotides of 5’-(UTR) and 523 nucleotides of 3’-(UTR) cloned into the pLitmus29 vector
(pL29 – Sbc10h7). Site-directed mutagenesis was done using the QuikChange II Site-Directed
Mutagenesis Kit according the manufacturer’s specifications (Stratagene, La Jolla, CA). Briefly,
complimentary oligonucleotides containing the desired mutations were designed using
Stratagene’s

web-based

QuikChange

Primer

Design

Program

(http://www.stratagene.com/qcprimerdesign) and ordered through Sigma-Genosys with desalting
for purification (Sigma-Aldrich Co., The Woodlands, TX) (Table 5). Further purification by
FPLC or PAGE, as recommended in the QuikChange II protocol, was not performed.
Mutagenesis reactions were performed by thermal cycling using PfuUltra High-Fidelity DNA
polymerase. All reactions were done in a 50μl volume in 0.5mL thin-walled tubes in the UNOII
Biometra Thermocycler. Cycling parameters are listed in Table 6. To make mutations analogous
to sbd alleles, the oligonucleotides used were H573R which alters histidine 573 to arginine (CAC
to CGC), P137L which alters proline 137 to leucine (CCA to CTA), and G760S which alters
glycine 760 to serine (GGC to AGC). To make mutations analogous to human disease-associated
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mutations, the oligonucleotides used were G760R which alters glycine 760 to arginine (GGC to
CGC) and S549I which alters serine 549 to isoleucine (AGC to ATC). The serine at 549 was also
converted to asparagine (AGC to AAC), as found in wild-type human trypsinogen, using
oligonucleotide S549N. For mutations changing cysteines in the disulfide-knotted domain,
oligonucleotides Cys2→Ser which alters cysteine 147 to serine (TGC to TCC), Cys3→Ser
which alters cysteine 153 to serine (TGC to TCC) and Cys5→Ser which alters cysteine 173 to
serine (TGC to TCC) were used. For mutations which alter each of the two putative start codons,
the oligonucleotides used were Met1→Leu and Met2→Leu which change methionines 1 and 24,
respectively, to leucine (ATG to TTG). To alter serine 49 to asparagine (AGC to AAC) and thus
remove the putative protein kinase C (PKC) phosphorylation site in the intracellular domain,
oligonucleotide PKC phos S49N was used. Following thermal cycling, mutagenesis reactions
were digested with the Dpn I endonuclease, specific for methylated and hemimethylated DNA,
to digest the parental DH5α-derived DNA template and thus select for newly synthesized
mutation-containing DNA. Upon digestion with Dpn I, mutagenesis reaction DNA was
transformed into XL1-Blue supercompetent cells. Presence of mutations was verified by
sequencing the entire Stubble coding region.
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Table 5. Sequences of oligonucleotides used in site-directed mutagenesis reactions
Oligonucleotide Name
Sequence (5’→3’)
F H573R
TCTCGAGCACCCGCCGTTGCGGTGG
F P137L
GATCAGCCCCAAGCTATGCTCCTTTGGCC
G760S F
GGGATCATCTCCTGGAGCATTGGCTGTGCCG
G760R F
GGGATCATCTCCTGGCGCATTGGCTGTGCCG
S549I F
CGTGGGCGGTAAGATCGCGGCCTTCGGTCG
S549N F
CGTGGGCGGTAAGAACGCGGCCTTCGGTCG
F Cys2→Ser
GTCGAGGGCACCTCCATGTTCGTGTGG
F Cys3→Ser
GTTCGTGTGGGAGTCCATCAAGTCCGAGG
F Cys5→Ser
CATGTTCGGCTCCTCCTGCACGCACAACT
F Met1→Leu
CCGGCACGTTACCGTTGAAGCAGCCAACT
F Met2→Leu
CGGCAGCCACCAAGTTGTGTCCCAAAAGG
F PKC phos S49N
TGCGGCGCGGAACAGGCGCAGTC
Only forward oligonucleotides and sequences are given. The reverse compliment of each
forward oligonucleotide sequence gives the corresponding reverse oligonucleotide sequence.
Point mutations induced by site-directed mutagenesis are shown in bold.

Table 6. Cycling parameters for site-directed mutagenesis
Segment
1
2

Cycles
1
12

Temperature
95ºC
95ºC
55ºC
68ºC
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Time
30 seconds
30 seconds
1 minute
7 minutes

Transgenic constructs
Construction of the wild-type hs-Sb+ transgene was described previously (Hammonds
2002; Bayer 2003). Briefly, a full-length 3.8 kb Stubble cDNA was cloned into the 2.8 kb
pLitmus29 vector and subsequently into the 8.9 kb pCaSpeR-hs heat-shock-inducible P-element
transformation vector to allow inducible expression of the transgene under heat-shock control.
Mutant transgenic constructs were generated by sub-cloning the mutagenized Stubble
cDNA (described above) from the pLitmus29 vector into pCaSpeR-hs. Mutagenized Stubble
DNA fragments were removed from pLitmus29 by digestion with BamHI/SpeI and were gel
purified following electrophoresis in 0.8% SeaPlaque GTG agarose (BioWhittaker Molecular
Applications, Rockland, ME) in 1X TAE buffer. Bands corresponding to the Stubble mutant
constructs were excised from the agarose and purified using the QIAquick Gel Extraction Kit
(Qiagen, Valencia, CA) and cloned into BglII/XbaI-digested pCaSpeR-hs using the Rapid DNA
Ligation Kit (Roche Diagnostics Corp., Indianapolis, IN). Ligation products were then
transformed into MAX Efficiency DH5α or TOP10 One Shot competent cells (Invitrogen,
Carlsbad, CA) according to manufacturer’s specifications with the following exceptions: MAX
Efficiency competent cells were used in 50μl aliquots and 1μl of undiluted ligation reaction (110 ng) was added for transformation. The resulting hs-Stubble mutant constructs were injected
into w1118 embryos to generate transgenic lines.
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CHAPTER THREE: RESULTS – CHARACTERIZATION OF STUBBLE
MUTANT ALLELES

At present, the mechanism by which Stubble-mediated extracellular proteolysis
influences the intracellular Rho1 signaling pathway to control of epithelial morphogenesis is
poorly understood. In order to better understand the role played by the Stubble protease in
epithelial morphogenesis, it is necessary to define Stubble action on a mechanistic level. One
approach to a better understanding of the mechanism of action of Stubble is to determine which
of the conserved domains found within this protease are necessary for its function. Using
sequence analysis and genetic interaction assays, I have genetically characterized and identified
functional domains of sixteen mutant alleles of the Stubble TTSP.

Stubble mutant alleles used in this study
In an attempt to determine which of the domains contained within the Stubble protease
are necessary for its function, we conducted sequence analysis of 16 recessive Stubble (sbd)
mutant alleles having several origins (see Table 1). The six sbdE(br)alleles were generated by
Ward et al. (2003) through EMS mutagenesis of a stock carrying the br1 allele. Mutagenized
chromosomes were allowed to undergo free recombination for several generations to remove
unlinked second-site mutations before being balanced.
The sbd46, sbd173 sbd177, sbd241, sbd258, sbd266, and sbd277 alleles were produced by EMS
mutagenesis of w1118 animals carrying isogenic second and third chromosomes (Ruggiero, 2006).
These alleles were outcrossed after balancing to remove extraneous mutations on the X and
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second chromosomes; however, this process did not allow free recombination and thus would not
have removed any second-site EMS-induced mutations carried on the third chromosome. It was
previously stated that sbd177 no longer carries the sbd mutation (Ruggiero, 2006). This was
confirmed by generating sbd177/sbd201 trans-heterozygotes. These animals are expected to have
reduced bristles and malformed legs and wings. In contrast, a wild-type phenotype was observed
indicating that the sbd177 allele had been lost from the stock. Thus, this allele was excluded from
further analysis.
The alleles sbdPNR11 and sbdVE3 were produced by EMS mutagenesis of st e animals and
sbd206 was produced by EMS mutagenesis of animals of the genotype ru cu ca (Appel, 1992).
Further information on these alleles is unavailable. Finally, sbd1 is a spontaneous mutation first
discovered by Sturtevant in 1926 and published by Dobshansky in 1930.

Sequencing of sbd alleles
sbdE(br) alleles
Genomic DNA from sbdE(br)/TM6B, Tb Hu e or sbdE(br)/sbdE(br)228 heterozygotes and the
br1 progenitor stock for the sbdE(br) alleles was sequenced on both strands through the entire
protein-coding region. Four differences from either of the published wild-type Stubble sequences
(Appel et al., 1993; gi (GenBank ID) 158511 and Adams et al., 2000; gi 7300108) were found in
all six sbdE(br) alleles (Table 7). In an S/T-rich portion of exon 7, the sbdE(br) alleles contain
sequence variation del2129_2131, an in-frame 3-bp deletion which eliminates the threonine
residue at amino acid 421, thereby reducing a string of 8 threonines to 7. Also found in the S/Trich region of exon 7 is sequence variation 2167A>G, a silent A-to-G single base change at
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cDNA nucleotide 2167. In exon 9, sequence variation 2752G>T, a silent G-to-T substitution at
nucleotide 2752, is found in all sbdE(br)alleles. Finally, in exon 10, sequence variation 3037C>T,
a single base change (C to T) at nucleotide 3037, produces no amino acid change. These four
variations are also found in the br1 progenitor stock and thus are considered polymorphisms and
are not attributed to the sbd phenotype observed in animals carrying these alleles. Four
previously published polymorphisms, all found in exon 6, were also identified in all six sbdE(br)
alleles and in the progenitor stock (Table 7). These include sequence variations
del(1727_1744)CAG, a 3-bp CAG in-frame deletion which reduces a string of seven glutamines
to six between amino acids 287 and 293; 1862C>A, a silent C-to-A point mutation at nucleotide
1862; 1913A>T, an A-to-T change at nucleotide 1913 that results in a serine-for-threonine
substitution at amino acid 349 and 1928C>T, a serine-for-proline substitution at amino acid 354
caused by a single C-to-T base change at nucleotide 1928 (Hammonds and Fristrom, 2006).
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Table 7. Polymorphisms of the Stubble locus
Sequence
Variationa, b

Amino Acid
Levelb

Allelesc

Description

1025T>C

4

silent

Silent T-to-C single base substitution at nucleotide 1025

sbd1

1150T>C

4

silent

Silent T-to-C single base substitution at nucleotide 1150

del(1727_1744)
CAG

6

delQ(287_293)

In-frame 3-bp deletion of a CAG repeat reduces a string of 7
glutamines to 6 between amino acids 287 and 293

1862C>A

6

silent

Silent C-to-A single base substitution at nucleotide 1862

1913A>T

6

T349S

A-to-T single base substitution at nucleotide 1913 results in a
threonine-to-serine substitution at amino acid 349

1928C>T

6

P354S

C-to-T single base substitution at nucleotide 1928 results in a
proline-to-serine substitution at amino acid 354

sbdVE3, sbdPNR11
sbd46, sbd173, sbd201, sbd241, sbd277, sbdE(br)20, sbdE(br)48,
sbdE(br)228, sbdE(br)448, sbdE(br)536, sbdE(br)623, sbdVE3, sbdPNR11,
br1
sbd46, sbd173, sbd201, sbd241, sbd277, sbdE(br)20, sbdE(br)48,
sbdE(br)228, sbdE(br)448, sbdE(br)536, sbdE(br)623, sbdVE3, sbdPNR11,
br1
sbd46, sbd173, sbd201, sbd241, sbd277, sbdE(br)20, sbdE(br)48,
sbdE(br)228, sbdE(br)448, sbdE(br)536, sbdE(br)623, sbdVE3, sbdPNR11,
br1
sbd46, sbd173, sbd201, sbd241, sbd277, sbdE(br)20, sbdE(br)48,
sbdE(br)228, sbdE(br)448, sbdE(br)536, sbdE(br)623, sbdVE3, sbdPNR11,
br1

del2090_2098

7

delSTT408_410

del2129_2131

7

delT421

2167A>G

7

silent

Silent A-to-G single base substitution at nucleotide 2167

2377C>T

7

silent

Silent C-to-T single base substitution at nucleotide 2377

2430A>G

7

H521R

A-to-G single base substitution at nucleotide 2430 results in a
histidine-to-arginine substitution at amino acid 521

sbdVE3, sbdPNR11

2752G>T

9

silent

Silent G-to-T single base substitution at nucleotide 2752

sbd46, sbd173, sbd201, sbd241, sbd277, sbdE(br)20, sbdE(br)48,
sbdE(br)228, sbdE(br)448, sbdE(br)536, sbdE(br)623, br1

2812G>A

9

silent

Silent G-to-A single base substitution at nucleotide 2815

sbd1

2827G>T

9

silent

Silent G-to-T single base substitution at nucleotide 2827

sbd1, sbd206

3001T>C

10

silent

Silent T-to-C single base substitution at nucleotide 3001

sbd258, sbd266, sbdVE3, sbdPNR11, isoline

3037C>T

10

silent

Silent C-to-T single base substitution at nucleotide 3037

sbd1, sbd46, sbd173, sbd201, sbd206, sbd241, sbd277, sbdE(br)20,
sbdE(br)48, sbdE(br)228, sbdE(br)448, sbdE(br)536, sbdE(br)623, br1

a
b
c

Exon

In-frame 9-bp deletion from nucleotide 2090 to nucleotide
2098 removes a serine, threonine, threonine (STT) repeat
from amino acids 408 to 410
In-frame 3-bp deletion of ACA reduces a string of 8
threonines to 7 at amino acid 421 in an S/T-rich region

sbd206, sbd258, sbd266, sbdVE3, sbdPNR11, isoline
sbd1, sbd46, sbd173, sbd201, sbd241, sbd277, sbdE(br)20,
sbdE(br)48, sbdE(br)228, sbdE(br)448, sbdE(br)536, sbdE(br)623, br1
sbd1, sbd46, sbd173, sbd201, sbd206, sbd241, sbd258, sbd266,
sbd277, sbdE(br)20, sbdE(br)48, sbdE(br)228, sbdE(br)448, sbdE(br)536,
sbdE(br)623, sbdVE3, sbdPNR11, br1, isoline
sbd258, sbd266, isoline

Nucleotide positions are in cDNA numbering corresponding to the published genomic sequence from a y; cn bw sp strain (Adams et al., 2000; gi 7300108).
Parentheses indicate uncertainty in the position of the variation.
Isoline refers to w1118; iso2; iso3 stock used as the progenitor for the sbd alleles produced by Ruggiero (2006).
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In addition to the eight polymorphisms identified, four of the six sbdE(br) alleles also
contain additional changes within the protease domain that are unique to each allele (Table 8;
Figure 9). Exon 11 of the sbdE(br)20 and sbdE(br)228 alleles contains single amino acid substitutions
resulting in missense mutations. In sbdE(br)20, a C-to-T change at nucleotide 3141 results in a
phenylalanine-for-serine substitution (TCC to TTC) at amino acid 758, and in sbdE(br)228, a G-toA change at nucleotide 3146 results in an arginine-for-glycine substitution (GGC to AGC) at
amino acid 760.

Table 8. Mutations identified in sbd alleles
Allele

Mutation

Allele

Mutation

sbdE(br)20

S758F

sbdPNR11

D737N

sbdE(br)48

Regulatory?

sbdVE3

P662L

sbdE(br)228

G760S

sbd206

Q446 Nonsense

sbdE(br)448

Q714 Nonsense

sbd1

Regulatory?

sbdE(br)536

Regulatory?

sbd258

G755E

sbdE(br)623

24bp deletion in intron
separating exons 10 and
11 – removes lariat
sequence

sbd266

P137L; T587N directly followed
by Δnt2630-2922 – causes
frameshift leading to truncation
after addition of 14 residues
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Figure 9. Locations of point mutations in sbd alleles.
Amino acid residue number is shown in the scale at the bottom. Stubble protein domains are shown: CD (cytoplasmic domain) aa 158, TM (transmembrane domain) aa 59-81, knot (disulfide knotted domain) aa 138-173, and serine protease domain from the
activation cleavage site at aa 543 to the C terminus at aa 787. The residues of the catalytic triad are denoted by solid vertical bars. The
boundary between exons 10 and 11 is also noted.
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The allele sbdE(br)448 contains a single amino acid substitution (C to T) at nucleotide 3008
which replaces the glutamine residue at amino acid position 714 with a stop codon, thus
truncating the protein 74 residues before its C-terminus and removing the catalytic serine and the
substrate binding site.
Finally, the allele sbdE(br)623 contains a 24-bp deletion within the intron separating exons
10 and 11. The deleted portion of the intron contains the lariat branch point consensus sequence
CTAAT, in which branch formation occurs at the underlined A (Mount et al., 1992). No
additional mutations were found in the coding region of the remaining two alleles, sbdE(br)48 and
sbdE(br)536, thus the mutations leading to the sbd phenotype in these mutants are presumed to be
of a regulatory nature.
sbd46, sbd173, sbd241 and sbd277 are all sbd201 alleles
Four of the putative sbd mutant alleles identified by Ruggiero (2006) in his EMS screen
are actually sbd201 alleles. Genomic DNA from sbd46, sbd173, sbd241, and sbd277 in homozygous
condition or in heterozygous condition with the w1118; iso2; iso3 progenitor line, as well as
genomic DNA from the wild-type w1118; iso2; iso3 progenitor line itself, was sequenced on both
strands through the entire protein-coding region (see Table 2). In each of these alleles, an
identical set of four previously published polymorphisms as well as five variations distinct from
either of the published wild-type sequences were found (Table 7). The four previously published
polymorphisms found in sbd46, sbd173, sbd241, and sbd277 (del(1727_1744)CAG, 1862C>A,
1913A>T and 1928C>T) as well as four of the five newly identified differences (del2129_2131,
2167A>G, 2752G>T and 3037C>T) are identical to the set of polymorphisms described for the
sbdE(br) and br1 alleles. The br1 stock was also the progenitor for the sbd201 allele used by
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Ruggerio (2006) to isolate new sbd alleles. The remaining variation is an A-to-G point mutation
at nucleotide 2586 in exon 8, which results in an amino acid substitution of arginine (CGC) for
histidine (CAC) at amino acid 573. This change has been attributed by Hammonds and Fristrom
(2006) to the sbd201 phenotype. The polymorphisms found in the w1118; iso2; iso3 progenitor
stock used in the screen from which sbd46, sbd173, sbd241, and sbd277 were identified support the
finding that these alleles are actually alleles of sbd201. The w1118; iso2; iso3 stock (isoline in
Table 7) contains three polymorphisms not observed in the sbd46, sbd173, sbd241, and
sbd277alleles. These include sequence variations del2090_2098, a 9-bp in-frame deletion in exon
7 that results in the deletion of one unit of a tandem repeat of serine, threonine, threonine (STT)
between amino acids 408 and 410; 2377C>T, a silent C-to-T point mutation at nucleotide 2377
in exon 7 and 3001T>C, a silent T-to-C point mutation at nucleotide 3001 in exon 10.
sbd258and sbd266
Genomic DNA from sbd258 and sbd266/TM6B Tb Hu e or w1118; iso2; iso3/sbd258 and
sbd266 heterozygotes was sequenced on both strands through the entire protein-coding region (see
Table 2). These alleles were produced from the w1118; iso2; iso3 progenitor stock, and carry all of
the polymorphic changes associated with the progenitor (Table 7). In addition, sbd258 contains a
single base change (G to A) at nucleotide 3132 which results in a glycine-to-glutamic acid amino
acid substitution at residue 755 (Table 8; Figure 9).
In addition to the polymorphisms observed in the progenitor stock, sbd266 contains a C-toA point mutation at nucleotide 2628, which results in a threonine-to-asparagine (ACC to AAC)
substitution at residue 587, followed by an out-of-frame 292-bp deletion from nucleotide 2630 to
nucleotide 2922 that adds 14 incorrect amino acids onto modified residue 587 (Asp) before
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reading into a stop codon and effectively truncating the protein before any of the catalytic triad
residues have been added (Table 8; Figure 9). In addition, sbd266 contains a C-to-T point
mutation at nucleotide 1278, which results in an amino acid substitution of leucine-for-proline at
amino acid 137.
sbdPNR11 and sbdVE3
Genomic DNA from sbdPNR11 and sbdVE3/TM6B, Tb Hu e heterozygotes or sbdPNR11 and
sbdVE3 homozygotes was sequenced on both strands through the entire protein-coding region (see
Table 2). The progenitor was not available for sequencing. Nine polymorphisms were identified
in both alleles, consistent with their origin from a common progenitor (Table 7). These include
sequence variants 1150T>C, a silent T-to-C point mutation at nucleotide 1150 in exon 2;
2430A>G, a single A-to-G base change at nucleotide 2430 resulting in an arginine-for-histidine
substitution

at

amino

acid

521

in

exon

7

and

del(1727_1744)CAG,

1862C>A,

1913A>T,1928C>T, del2090-2098, 2167A>G and 3001T>C. In addition to the polymorphic
variations, sbdPNR11 contains a G-to-A point mutation at nucleotide 3077 which results in the
substitution of an asparagine (AAT) for an aspartic acid (GAT) at amino acid 737 (Table 8;
Figure 9). sbdVE3 also contains a sequence variation in addition to the polymorphisms identified.
This variant is a single C-to-T point mutation at nucleotide 2853 which leads to substitution of
leucine (CTC) for proline (CCC) at amino acid 662. This proline is a conserved residue in a
conserved region of the protease domain (Table 8; Figure 9).
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sbd206
Genomic DNA from sbd206 ru cu e ca/TM6B, Tb Hu e heterozygotes or sbd206 ru cu e ca
homozygotes was sequenced on both strands through the entire protein-coding region (see Table
2). Five differences from either of the published wild-type sequences were found. Four of the
five differences were polymorphic sequence variations (Table 7): del2090_2098, 2167A>G,
2827G>T, a silent G-to-T single base change at nucleotide 2827 in exon 9 and 3037C>T. The
fifth and more significant difference is a C-to-T single base change at nucleotide 2324 which
results in a nonsense mutation, substituting a stop codon (TAA) for the glutamine (CAA) residue
at amino acid position 446 in the stem region (Table 8; Figure 9). This mutation results in
truncation of the Stubble protease in exon 7 prior to the start of the protease domain.
sbd1
Genomic DNA from sbd1 st ro e ca homozygous animals was sequenced on both strands
through the entire protein-coding region. Six differences from either of the published wild-type
sequences were found (Table 7). Four are polymorphic sequence variations found in other sbd
alleles (del2129_2131, 2167A>G, 2827G>T and 3037C>T). The remaining two variations are
both silent changes not found in any of the other sequenced alleles. These include sequence
variants 1025C>T and 2812G>A (Table 7), a C-to-T single base change at nucleotide 1025 in
exon 4 and a G-to-A change at nucleotide 2812 in exon 9, respectively. Though these two
variations have only been identified in one allele, they are most likely polymorphisms because
they are silent changes. No other changes have been identified in the coding region of sbd1,
suggesting that the mutation which causes the sbd phenotype may be of a regulatory nature.
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Second-site noncomplementation analyses between sbd mutations and mutations in Rho1
pathway members
Genetic interaction studies of molecularly characterized mutant alleles of a gene can be a
useful tool to rank the relative severity of different mutations. This, in turn, can establish the
relative importance of the conserved domains within the protein to protein function and
potentially link individual domains to different developmental functions.
In order to genetically characterize the twelve mutant sbd alleles in Table 8, we first
determined the strength of interaction between these alleles and mutations in Rho1 pathway
members using second-site noncomplementation (SSNC) analyses. SSNC assays test pairs of
mutant alleles in double heterozygous condition (i.e. Rho1/+; Sb/+). Strong genetic interactions
observed in SSNC assays frequently indicate that two genes function in the same signaling
pathway or act directly on the same developmental process. Previous work in our lab has shown
that different combinations of Rho1 and Stubble alleles can result in high frequencies of animals
with leg malformation in SSNC assays (Bayer et al., 2003). For example, the dominant alleles
Sb63b and Sb70 interact very strongly with Rho1 alleles and a Rho1 deficiency, with malformation
frequencies ranging from 59-95%. In contrast, the recessive sbd105 deficiency allele shows weak
interaction with Rho1 alleles and moderate interaction with a Rho1 deficiency. No interactions
were observed with the recessive sbd1 or sbd201 alleles. In these studies, interactions were defined
as strong when 50% of animals of the relevant genotype had at least one malformed leg,
moderate when 25 to 49% of animals show malformation, and weak when 5 to 24%
malformation is exhibited (Bayer et al., 2003).
To extend these data, the 12 sbd alleles analyzed in this study were tested for SSNC
interactions with mutations in Rho1 and zipper, a member of the Rho1 signaling pathway, and 10
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were tested for dominant interactions with the Rho172O allele. A majority of the SSNC assays
between sbd mutant alleles and Rho1 mutant alleles were carried out by an undergraduate
assistant, Stephanie Stallworth, from Daytona Beach Community College participating in the
NIH Bridges to the Baccalaureate Program who worked under my supervision.
Genetic interaction data for sbd and Rho1 mutant alleles demonstrate that sbd alleles
show either weak or no interaction with Rho172O, Rho1J3.8, Rho1E.3.10 and Rho1k02107b (Table 9).
Leg malformation frequencies range from 0 to 18%, with the majority of Rho1; sbd heterozygous
combinations exhibiting less than 5% malformation. In combination with the zipper mutant
zipEbr, three sbd alleles (sbd258, sbdPNR11 and sbd206) exhibit moderate frequencies of
malformation while the remaining nine alleles exhibit weak or no interaction (Table 9). Because
all twelve sbd alleles are inviable as homozygotes, the trans-heterozygous combination
sbd*/sbd1, was used for dominant interaction assays. With the exception of sbdVE3/sbd1, Rho172O
shows very strong dominant interactions with all ten sbd*/sbd1 trans-heterozygotes tested (Table
9). However, the background malformation rates for these sbd*/sbd1 combinations range from 59
to 100% (see sbd/sbd combinations in Table 9) and thus severely limit the usefulness of the data
obtained from these dominant genetic interaction assays. In contrast, a weak interaction was
observed between Rho172O and sbdVE3/sbd1 trans- heterozygotes, which have a background
malformation rate of 0% (see sbdVE3/sbd1 in Table 9).
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Table 9. Second-site noncomplementation analyses of sbd mutant alleles
sbd201e

sbd201

sbd1

Rho172O

Rho1J3.8

Rho1E3.10

Rho1k02107b

zipEbr

Rho172O; sbd1

sbd258

89.1 (46)

97.6 (43)

78.4 (51)

0 (64)

1.1 (92)

2.4 (83)

0 (73)

27.8 (126)

98.5 (66)

sbd266

100 (6)
semi-lethal

100 (33)

80.7 (57)

0 (93)

0.8 (130)

1.2 (85)

2.2 (91)

21.3 (108)

97.6 (41)

sbdE(br)20

100 (50)

100 (110)

100 (51)

1.0 (99)

0 (55)

4.2 (142)

7.3 (82)

18.9 (122)

100 (61)

sbd

E(br)48

100 (57)

100 (99)

90.0 (120)

0 (50)

0 (39)

4.4 (135)

2.4 (83)

4.6 (109)

97.5 (79)

sbd

E(br)228

100 (64)

100 (66)

80.9 (42)

1.3 (79)

0.9 (108)

0.8 (113)

2.3 (86)

1.0 (98)

83.3 (60)

sbdE(br)448

94.1 (51)

100 (86)

97.1 (70)

0 (103)

0 (74)

1.6 (122)

0 (107)

11.2 (107)

100 (77)

sbd

E(br)536

100 (78)

100 (38)

97.3 (74)

2.5 (80)

17.5 (120)

7.0 (113)

8.7 (92)

22.2 (81)

100 (67)

sbd

E(br)623

97.9 (47)

100 (135)

95.4 (65)

0.9 (106)

8.0 (87)

3.8 (133)

3.2 (93)

11.8 (68)

98.8 (83)

sbd

VE3

0 (76)

0 (88)

0 (13)

0 (115)

0 (117)

1.6 (63)

1.9 (104)

0.8 (124)

16.7 (30)

sbd

PNRII

100 (44)

100 (34)

96.4 (28)

0 (122)

1.1 (90)

3.7 (107)

0.9 (116)

35.8 (120)

100 (35)

sbd

206

100 (64)

100 (115)

ND

2.3 (129)

4.0 (100)

11.9 (109)

5.4 (93)

33.6 (110)

ND

sbd

1

19.8 (116)

45.8 (205)

ND

1.9 (104)

1.7 (172)

1.6 (122)

6.7 (149)

ND

0.7 (143)
72O

258

258

201

Animals are either doubly heterozygous, e.g. Rho1 /+; sbd /+, or trans-heterozygous, e.g. sbd /sbd e. The numbers shown
indicate the percentage of animals with malformed legs, with the total number of animals of the indicated genotype scored shown in
parentheses. ND, not determined.
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Lethal-phase analysis of sbd mutant alleles
To characterize the effects of each mutation on Stubble protease function, lethal-phase
studies were conducted. These experiments were done in the same manner as described by Ward
et al. (2003) to characterize the sbdE(br) alleles (see Methods). These experiments reveal that
sbd258 exhibits predominantly embryonic lethality, with only 10% of embryos hatching (Table
10). Those animals that do hatch die as early first instar larvae. Four of the six mutants tested,
sbd266, sbdPNR11, sbdVE3, and sbd206, are predominantly larval lethal. The remaining allele, sbd1,
shows broad stage-specific lethality with ~45% viable adults.

Table 10. Lethal phase analysis of sbd mutants
Embryonic
lethalitya
89.6 ± 1.7

Larval
lethalityb

Pupal
lethalityc

100

NA

sbd

266

4.0 ± 0.4

100

NA

sbd

PNR11

8.0 ± 1.9

100

NA

sbd

VE3

29.1 ± 4.1

100

NA

sbd

206

6.8 ± 0.1

100

NA

sbd

1

26.4 ± 6.4

31.0 ± 2.6

10.8 ± 2.5

sbd 258

a

Mean ± SE of embryonic lethality from three independent experiments. Embryonic lethality
was calculated as (number of dead embryos/total number of mutant embryos) x 100.
b
Mean ± SE of larval lethality from three independent experiments. Mutant larvae were picked
as newly hatched first instar larvae. Larval lethality was calculated as [(total number of mutant
larvae – number of pupae)/total number of mutant larvae] x 100.
c
Mean ± SE of pupal lethality from three independent experiments. Pupal lethality was
determined by allowing those larvae from the larval lethality assay that pupariated to eclose.
Adults were counted and pupal lethality was calculated as [(total number of pupae – number of
adults)/total number of pupae] x 100. NA, not applicable.

51

Experiments in progress
Classification of sbd mutant alleles.
In 1932, Muller developed a naming system to classify mutations based on their behavior
in various genetic situations (Muller, 1932). He coined the terms amorph, hypomorph,
hypermorph, antimorph and neomorph to define the genetic behavior of various classes of alleles
he observed. In Muller’s terminology, an amorphic mutation results in a complete loss of gene
function while a hypomorphic mutation causes a partial loss of gene function. Hypermorphic,
antimorphic (also called dominant negative) and neomorphic mutations result in a gain of gene
function. A hypermorph causes an increase in normal gene activity (e.g. transcription), an
antipmorph is a dominant mutation that acts antagonistically to normal gene activity, and a
neomorph is a mutation that results in a gain of novel gene activity. If the behavioral
classification of an allele can be determined, it can prove useful in the interpretation of classical
and molecular genetic data.
To classify the nine non-regulatory mutations as well as the three putative regulatory
mutations in our sbd alleles (see Table 8) as amorphic, hypermorphic or gain-of-function, the
developmental progress and lethal phase of sbd homozygotes was monitored and compared with
that of trans-heterozygous sbd*/Df(3R)sbd105 animals. The Df(3R)sbd105 allele contains a
deficiency which removes the entire Stubble locus. In trans-heterozygous condition with a
deficiency, an amorphic mutant should exhibit identical developmental progress and lethal phase
as the amorphic homozygote since both genotypes result in complete loss of gene function. A
hypomorphic mutant should exhibit a more severe phenotype over a deficiency than as a
homozygote. Hypermorphic mutations should exhibit a less severe phenotype over a deficiency
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than as a homozygote. The phenotype of dominant negative homozygous mutations compared to
dominant negative over a deficiency is hard to predict; however, the severity of phenotype of a
dominant negative can be reduced by over-expressing the wild-type protein. In contrast, the
phenotype of a hypermorphic mutation is expected to become worse if the the wild-type protein
is over-expressed. Finally, the phenotype of neomorphic mutations as homozygotes or over a
deficiency is expected to be similar; however, over-expression of wild-type protein will have no
effect on the phenotype.
At present, only sbd258, sbdPNR11, sbd206, and sbdE(br)228 have been tested. All other alleles
(see Table 8) remain to be analyzed. As homozygotes, sbd258 animals are predominantly
embryonic lethal, whereas sbdPNR11, sbd206, and sbdE(br)228 animals exhibit predominantly larval
lethality (see Table 10). As trans-heterozygotes with Df(3R)sbd105, all four alleles show
improved development with at least half of the animals surviving to adulthood, suggesting that
all are associated with gain-of-function mutations.
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CHAPTER FOUR: RESULTS – SCREEN FOR G PROTEIN-COUPLED
RECEPTORS THAT INTERACT WITH STUBBLE TO CONTROL LEG
DEVELOPMENT

It has been proposed that the Stubble protease operates through an “outside-in” signaling
mechanism during leg development to either act in parallel with or directly regulate Rho1
signaling. Four vertebrate TTSPs have also been shown to operate via an apparent outside-in
signaling mechanism using the GPCR PAR-2. In addition, GPCRs are known to be major
upstream regulators of vertebrate Rho signaling through activation of heterotrimeric G proteins.
Because GPCRs have been linked to both extracellular proteolytic activity and intracellular Rho
signaling, I asked if the known non-odorant and non-gustatory G protein-coupled receptors
within the Drosophila genome interact genetically with Stubble in the control of leg imaginal
disc morphogenesis. Though it is not inconceivable that an odorant or gustatory receptor could
link Stubble proteolytic activity with Rho1 signaling in epithelial development, these receptor
types were excluded based on their known involvement in the nervous system.
Excluding the 119 gustatory and odorant receptors, 147 genes encoding G proteincoupled receptors have been identified in the Drosophila genome. Four of these have not been
mapped to the genome sequence and thus were also excluded. To screen for G-protein-coupled
receptors potentially involved in leg morphogenesis, SSNC assays were performed by mating
heterozygous Stubble mutant animals (i.e., red Sb63be/TM6B, Tb Hu e) with heterozygous or
homozygous animals carrying a deficiency uncovering the GPCR, or a lethal transposable
element insertion or mutation in the GPCR. Resulting adults of the doubly mutant heterozygous
class, e.g., GPCR/+; red Sb63be/+, were scored for frequency of leg malformation. Stubble
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mutant animals exhibit a background malformation rate of ~2%. A minimum increase in
malformation rate of 20-fold above background is considered significant, and thus only crosses
producing greater than 40% malformation in the doubly heterozygous F1 class were deemed
significant. At present, 98 of the 147 GPCR-encoding genes have been tested for genetic
interactions with Stubble in a total of 155 individual assays. A majority of this work was done by
Nikette Benjamin, an undergraduate research assistant who worked under my supervision. From
this screen, we identified 4 interacting chromosomal regions which collectively uncover 8
GPCRs (Table 11). A list of all deficiencies and mutations tested is given in Appendix 1.

Table 11. GPCR deficiencies showing strong interactions with Sb63b
Deficiency

Region Uncovered

GPCRs Uncovered

% mlf with Sb63b

Df(2L)Exel7027

26F6-27B1

GRHR

57.1 (28)

Df(2R)Exel6068

56A1-56B5

5-HT1A, 5-HT1B

34.5a (29)

Df(3L)Exel6084

61B2-61C1

mthl9, mthl10, mthl14

80.4 (92)

Df(3R)red-P52

88A4-88B2

CG9918, DopR

87.5 (40)

a

63b

The percent malformation for Df(2R)Exel6068/+; red Sb e/+ animals was less than 40%;
however, this deficiency was kept for further evaluation due to the low number of double
heterozygote animals produced in the primary assay.

Df(2L)Exel7027
The first interacting region, 26F6-27B1, is uncovered by the deficiency Df(2L)Exel7027.
This region contains 21 genes, including the GPCR gonadotropin-releasing hormone receptor
(GRHR). Doubly heterozygous Df(2L)Exel7027/+; red Sb63b e/+ animals exhibit 57% leg
malformation, suggesting that one or more of the 21 genes deleted on the deficiency
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chromosome is involved in leg disc morphogenesis. Because a high frequency of malformation
was obtained for the deficiency in combination with Sb63b, we performed a series of follow-up
experiments to verify the initial genetic interaction, and reduce the size of the interacting region
carrying the interacting gene(s) (Table 12). To assay for consistent interaction between the
deficiency allele and the Stubble locus, Df(2L)Exel7027 animals were crossed to animals
carrying Sb70, a second mutant allele of Stubble. Animals of the doubly heterozygous
Df(2L)Exel7027/+; Sb70/+ class exhibit 61% leg malformation, consistent with the malformation
frequency obtained with Sb63b. Deficiency animals were also mated with animals carrying br1, a
mutant allele of broad. The broad locus encodes an ecdysone-inducible gene which interacts
genetically with the Stubble locus (Beaton et al., 1988). The br1/Y; Df(2L)Exel7027/+ male
progeny from this cross exhibit only 6% malformation indicating that Df(2L)Exel7027 does not
interact dominantly with br1. This low malformation rate does not necessarily exclude the
(unidentified) interacting gene from involvement in the ecdysone hierarchy. Previous experience
in our laboratory has shown that genetic interactions can be very allele specific where loss-offunction alleles do not always show interactions while gain-of-function alleles of the same gene
may. For example, null alleles of the non-muscle myosin heavy chain gene, zipper, are noninteractive in SSNC assays, whereas weak gain-of-function alleles of this gene, e.g. zipEbr, are
interactive. A reasonable explanation for these observations is that one functional copy of the
zipper gene product is sufficient for proper development. However, because the zipper protein
functions as a dimer, the presence of a weak gain-of-function allele results in a high proportion
of unproductive dimers and interferes with the function of the wild-type gene. Further assays
with mutants of Rho1 and Notopleural (Np), a genetic locus that potentially cooperates with the
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Stubble locus in regulation of bristle formation and leg development (Ruggerio, 2006), are
pending.

Table 12. Second-site noncomplementation analyses with Stubble interactors
Deficiency

Sb70

Rho1E3.10

Rho1J3.8

Np2

Np125A

br1/Y

Df(2L)Exel7027

61.3 (106)

ND

ND

ND

ND

6.3 (32)

Df(2R)Exel6068

58.4 (89)

ND

ND

ND

ND

38.6 (44)

Df(3L)Exel6084

95.6 (68)

2.3 (88)

5.6 (72)

6.2 (97)

5.0 (140)

33.3 (39)

Df(3R)red-P52

ND

ND

ND

79.4 (63)

80.0 (55)

ND

E3.10
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Animals are doubly heterozygous, e.g. Rho1
/+; Df(3R)red-P52/+, or + Sb /Df(3R)red-P52
+. The numbers shown indicate the percentage of animals with malformed legs, with the total
number of animals of the indicated genotype scored shown in parentheses. ND, not determined.

Df(2R)Exel6068
A second genomic region showing interaction with Sb63b is 56A1-56B5. This region
contains 16 genes, including the GPCRs 5-HT1A and 5-HT1B, and is uncovered by
Df(2R)Exel6068. Doubly heterozygous animals, i.e., Df(2R)Exel6068/+; red Sb63b e/+, exhibit
35% malformation (Table 11). This malformation frequency is below the 40% threshold
considered significant, but due to the low number of progeny produced in the primary cross,
secondary SSNC assays were done to determine the reliability of the data (Table 12). Animals of
the genotype Df(2R)Exel6068/CyO were crossed to Sb70/TM6B, Tb Hu e animals. The resulting
doubly heterozygous Df(2R)Exel6068/+; Sb70/+ class, which contained three times as many
animals as the class of interest in the original screen, exhibits 58% leg malformation. Further
evidence that Df(2R)Exel6068 uncovers an interacting gene comes from the moderate interaction
observed for Df(2R)Exel6068 in the presence of br1. Thirty-nine percent of br1/Y;
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Df(2R)Exel6068/+ animals exhibit leg malformation, suggesting that an interacting gene(s)
contained within the region uncovered by Df(2R)Exel6068 is involved in ecdysone signaling. It
will be interesting to determine the strength of genetic interactions between Df(2R)Exel6068 and
Rho1 and Np alleles.

Df(3L)Exel6084
A third deficiency which shows very strong interaction with Sb63b is Df(3L)Exel6084.
This stock carries a deletion of genomic region 61B2-61C1, which completely removes 43
genes, including the GPCRs methuselah-like (mthl) 9, mthl10 and mthl14. Mutant
Df(3L)Exel6084 animals exhibit 80% leg malformation in trans-heterozygous condition with
Sb63b(Table 11). The high frequency of malformation observed implies a very strong interaction
between Stubble and a gene(s) within the deleted region, thus a number of secondary
experiments have been done to determine which deleted gene product interacts with Stubble and
to further define the role of the deleted region in leg development (Table 12).
To verify the strength of the interaction observed between the deficiency chromosome
and Stubble, Df(3L)Exel6084 animals were crossed to mutant Sb70 animals. The transheterozygous Df(3L)Exel6084/Sb70 animals exhibit 96% leg malformation, consistent with the
data obtained with Sb63b. To test for further interaction with ecdysone-responsive genes,
Df(3L)Exel6084 animals were crossed to br1 mutants. From the br1 assay, a moderate
malformation frequency of 33% was observed for progeny of the genotype br1/Y;
Df(3L)Exel6084/+. Interestingly, only very weak interactions were observed between
Df(3L)Exel6084 and Rho1E3.10 or Rho1J3.8 (2% and 6%, respectively) or between Df(3L)Exel6084
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and the zipper allele, zipEbr (12%; data not shown). Similarly, weak interactions were observed
for Df(3L)Exel6084 in combination with the Notopleural alleles Np125A and Np2 (5% and 6%,
respectively). Collectively, these data raise the possibility that the interacting gene(s) uncovered
by Df(3L)Exel6084 may cooperate with Stubble to regulate leg development through a pathway
independent of Notopleural or Rho1.
In an attempt to identify the interacting gene(s) uncovered by Df(3L)Exel6084, nine
additional deficiencies which overlap the 61B2-61C1 genomic region were tested for SSNC with
Sb63b (Table 13; Figure 10). Of the nine deficiencies tested, two, Df(3L)BSC128 and
Df(3L)Exel9057, show significant interactions (79% and 51%, respectively) in combination with
Sb63b. This suggests that there are two interacting genes within the deleted region.
Several inconsistencies are apparent from the overlapping deficiency map shown in
Figure 10. Based on the published breakpoints, Df(3L)ED201, which shows no interaction with
Sb63b, encompasses both strongly interacting deficiencies as well as the original deficiency line
Df(3L)Exel6084. In addition, Df(3L)BSC126, which displays moderate interaction in
combination with Sb63b (Table 13), completely overlaps with the strong interactor Df(3L)Exel
9057. It has been our experience that the published breakpoints for many deficiencies are
unreliable, thus we are currently defining the molecular breakpoints of the deficiencies shown in
Figure 10 using molecularly defined lethal P-element insertions and mutations to assay for noncomplementation when in combination with the various deficiencies. The deficiencies
overlapping Df(3L)Exel6084 are also being mated to one another to determine whether the
genomic overlaps are real (Table 14). Though only a few of these experiments have been
completed, several informative pieces of data have been obtained. For example,
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Df(3L)BSC128/Df(3L)7C animals are viable, indicating that the left boundary of Df(3L)7C does
not likely extend as far to the left as indicated by the dashed line (region of uncertainty) in
Figure10. The Df(3L)ED201/Df(3L)7C combination, however, is lethal, indicating that, though
the left breakpoint of Df(3L)7C may be much farther to the right than indicated, there is still
some region of overlap between Df(3L)7C and Df(3L)ED201. Df(3L)ED201 also exhibits
lethality in combination with Df(3L)BSC128. This confirms the predicted overlap between these
two deficiencies but does not explain how Df(3L)BSC128 exhibits strong interaction with Sb63b
while Df(3L)ED201 shows no interaction with the same allele. Additional assays are necessary to
resolve this issue. As predicted by their molecular breakpoints, none of the deficiencies
Df(3L)BSC121, Df(3L)BSC128 or Df(3L)BSC125 is lethal in combination with Df(3L)Exel9057.
These data confirm that there is likely no region of overlap between the these BSC deficiency
chromosomes and Df(3L)Exel9057. In contrast, Df(3L)Exel9057 shows partial lethality in
combination with Df(3L)BSC126. Interestingly, the few animals that survive to adulthood show
no malformation. This is consistent with the semi-lethal phenotype of homozygous
Df(3L)Exel9057 animals.

Table 13. Deficiencies overlapping Df(3L)Exel6084
Deficiency

Genomic Region Uncovered

Df(3L)BSC126
Df(3L)BSC125
Df(3L)BSC128
Df(3L)Exel6083
Df(3L)Exel9057
Df(3L)ED201
Df(3L)7C
Df(3L)BSC121
Df(3L)ED4079

61B3-61C1
61B3
61B2
61A6-61B2
61C1
61B1-61C1
61B2-61C
61B2
61A5-61B1
60

63b

% mlf with Sb
26.6
25.0
79.4
3.2
51.2
0.0
5.3
35.8
0.0

mthl14
61A5

61A6

61B1

61B2

61B3

mthl9
mthl10
61C1

61C2

61C3

Exel6084
ED4079

Exel6083
7C
ED201
BSC121
BSC128

No Interaction
Moderate Interaction
Strong Interaction

BSC125
BSC126
Exel9057

Figure 10. Deletion map showing breakpoints for Df(3L)Exel6084 and overlapping deficiencies.
The scale along the top shows the genomic region. Positions of the 3 GPCRs uncovered by Df(3L)Exel6084 are denoted with
arrows. Positions of molecularly mapped lethal P-element insertions and mutations are denoted by arrowheads. Molecular
breakpoints have not been determined for 7C, thus the extent of the deleted region is unknown. The area of uncertainty is
indicated with dashed lines.
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Table 14. SSNC analyses of deletions overlapping Df(3L)Exel6084
Df(3L)7C
Df(3L)Exel6084
Df(3L)ED201
Df(3L)BSC128
Df(3L)Exel9057
Df(3L)BSC125
Df(3L)BSC126
Df(3L)BSC121

Df(3L)Exel6084

Df(3L)ED201

Df(3L)BSC128

Df(3L)Exel9057

Df(3L)BSC125

Df(3L)BSC126

ND
lethal
0 (40)
ND
ND
ND
ND

ND
ND
lethal
ND
ND
0 (141)
ND
ND
ND
0 (19)
ND
ND
ND
semi-lethal
ND
ND
ND
ND
2.2 (45)
ND
ND
Animals are trans-heterozygous, e.g., Df(3L)Exel6084/ Df(3L)7C. The numbers shown indicate the percentage of animals with

malformed legs, with the total number of animals of the indicated genotype scored shown in parentheses. ND, not determined.
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Df(3R)red-P52
The fourth and final genomic region showing strong interaction with Stubble is 88A488B2, which is uncovered by Df(3R)red-P52 (Table 11). This region contains at least 43 genes,
including the GPCRs CG9918 and Dopamine Receptor (DopR). Animals of the Df(3R)redP52/red Sb63b e class exhibit 88% leg malformation. Interestingly, the malformation observed in
this class is not typical of the malformation phenotype normally observed (see Figure 6). All
malformed Df(3R)red-P52/red Sb63b e animals have at least one excessively bowed tibia on the
third set of legs that twists slightly to the outside of the body such that it crosses the femur when
the legs are folded. The femurs, however, are all of the wild-type length and shape. Due to its
subtle nature, this phenotype would generally be scored as wild-type when seen in an individual
animal. However, since almost 90% of animals of the genotype Df(3R)red-P52/red Sb63b e
exhibit this phenotype, the deficiency was considered worthy of additional experiments.
In an attempt to further define the nature of the interaction observed between Df(3R)redP52 and the Stubble locus, deficiency animals were crossed to Np125A and Np2 (Table 12). As
with Sb63b, Df(3R)red-P52 shows very strong interaction in combination with both Np125A and
Np2, yielding malformation frequencies of 80% and 79%, respectively. The phenotype seen in
combination with Notopleural mutants is the same as that observed in Df(3R)red-P52/red Sb63b e
animals. Further SSNC and dominant interaction analyses will be performed between Df(3R)redP52 and Sb70, Rho1E3.10, Rho1J3.8 and br1.
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CHAPTER FIVE: DISCUSSION

To understand the role that TTSPs play in development, homeostasis and disease
progression, it is necessary to understand their mechanism of action. The Stubble protease serves
as an excellent model in which to study the mechanism by which TTSPs interact with
intracellular signaling pathways to regulate developmental processes. In this study, I have
attempted to develop a greater understanding of the mechanism of action of the Stubble TTSP
using two distinct approaches. First, I sequenced 12 mutant alleles of Stubble to determine which
of the conserved domains contained within the protease are necessary for proper function of
Stubble. Most of the mutations identified are located within or directly effect the protease
domain, indicating that this domain is necessary for function. One mutation was found outside of
the protease domain, but the relevance of this mutation to protease function has not been
established. Second, I performed a genetic interaction screen of the non-gustatory, non-odorant
GPCRs within the Drosophila genome in an attempt to find a target of the Stubble protease.
Though no individual targets have been identified to date, a few promising leads have been
obtained which are currently being investigated further.

Sequencing of Stubble mutant alleles
i.) Identification of four sbd alleles as sbd201
In this study I show that four of the putative sbd alleles (sbd46, sbd173, sbd241 and sbd277)
isolated by Ruggiero (2006) are actually sbd201 alleles. An overview of the strategy used by
Ruggiero (2006) to identify enhancers of the recessive sbd201 leg and bristle phenotypes is shown
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in Figure 11. In the strategy, a tester stock with the genotype Pm/CyO; red sbd201 e/TM6B, Tb Hu
e was mated to mutagenized animals (G1 cross in Figure 11). It is possible that during the
subsequent recovery and isolation of the enhancer chromosome, a recombined sbd201
chromosome lacking the recessive ebony marker could have been recovered rather than the
enhancer of sbd chromosome. As a consequence, at one or more points during this screen, the
sbd*/sbd201 class may have been confused with the sbd201/sbd201 class resulting in isolation of the
sbd201 allele rather than the sbd* allele. The sequence data support the possibility that the tester
and enhancer chromosomes were exchanged: sbd201 was produced in an earlier EMS screen
which used br1 as the progenitor stock (Beaton et al., 1988), and the polymorphisms found in
sbd46, sbd173, sbd241, and sbd277 are identical to those found in br1 and sbd201. The data presented
here differ from the findings of Hammonds and Fristrom (2006) in that both sbd201 and its br1
progenitor lack the del2090_2098 sequence variant in exon 7. This deletion was observed in the
w1118; iso2; iso3 progenitor stock used in Ruggiero’s EMS screen but was not found in the sbd201
or br1 stocks that I sequenced.
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Figure 11. A schematic overview of the Ruggiero sbd201 enhancer screen strategy.
Taken from Ruggiero, 2006.
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ii.) Effects of protease domain mutations on Stubble activity
Of the 12 sbd alleles sequenced, 8 carried specific mutations in the protein coding region.
In every case, mutations that are very likely to affect Stubble proteolytic function (see below)
were observed. In 2 cases additional mutations outside the proteolytic domain, were also
identified.
Upon activation of trypsin-like serine proteases, approximately 85% of the structures of
the protease domain remain organized identically and in the same conformation in the active
peptide as they were in the inactive zymogen. The remaining 15% of the protease domain (the
activation domain), which includes the substrate binding site and the oxyanion hole (see below),
undergoes a series of conformational changes. The folding of the activation domain is facilitated
by four conserved glycine residues which serve as hinges around which activation domain
segments move to form the active enzyme. Upon folding, the activation domain becomes ordered
while forming a closed domain that is stabilized by a salt bridge between the now-liberated Nterminus of the activation cleavage site isoleucine, Ile16 (Ile544 in Stubble), and aspartic acid
194 (Asp737 in Stubble; Gombos et al., 2008) (Note: When giving coordinates for amino acid
residues in the protease domain, the chymotrypsinogen numbering system will be used unless
otherwise noted). Formation of the Ile16-Asp194 salt bridge is also necessary to form a structural
linkage between the catalytic triad and the oxyanion hole during substrate binding (Figure 12).
The oxyanion hole is formed by the backbone amide NHs of Gly193 (Stubble Gly736) and
catalytic Ser195 (Stubble Ser738) and forms a pocket of positive charge that works to stabilize
the negatively charged oxyanion of an intermediate structure during substrate binding (Matthews
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et al., 1975). Incomplete folding of the activation domain in the zymogen results in inactivity of
the protease.
The main chain residues 214-216 (Stubble 758-760) make up the substrate binding site
and form an antiparallel beta sheet with the backbone P1-P3 residues of the substrate (Figure 13).
Hydrogen bonds form between the carbonyl oxygen of Ser214 (Stubble Ser758) and the amide
NH of the P1 residue, the amide NH of Trp215 (Stubble Trp759) and the carbonyl oxygen of P2
and the carbonyl of Gly216 (Stubble Gly760) and the amide NH of P3. These interactions are
essential for efficient proteolysis of the substrate. In addition to the primary substrate binding
site, residues 214-216 form a portion of one wall of the S1 subsite (specificity pocket; Figure
14), and the carbonyl of Ser214 forms a hydrogen bond with the catalytic histidine. These
structural interactions form a connection between the substrate binding site, the S1 site, and the
catalytic triad (reviewed in Hedstrom, 2002).
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Figure 12. Structure of chymotrypsin showing positioning of the oxyanion hole.
The oxyanion hole is structurally linked to the Ile16-Asp194 (Stubble Ile544-Asp737) salt bridge
and the catalytic triad residues His57, Asp102 and Ser195 (Stubble His590, Asp640 and Ser738)
via catalytic Ser195 (Stubble Ser738). Figure taken from Hedstrom, 2002.
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Figure 13. Mechanism of substrate binding for serine proteases.
Catalytic groups of chymotrypsin-fold serine protease are depicted interacting with a substrate at
its P1 site (substrates are hydrolyzed at the P1-P1’ bond). Five enzyme-substrate hydrogen bonds
at positions P1 and P3, including those involving Ser214 and Gly216 (Ser758 and Gly760 in
Stubble), are shown in addition to hydrogen bonds among members of the catalytic triad. The
interaction of amide NH of Trp215 (Stubble Trp759) with the carbonyl oxygen of the P2 residue
is not labeled. Figure and legend taken from Perona and Craik, 1997.
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Figure 14. Schematic diagram of the S1 subsite of chymotrypsin interacting with a substrate.
The S1 subsite is composed of three walls formed by residues 189-192, 214-216 and 224-228
(732-735, 758-760 and 768-772 in Stubble). Residues 214, 224 and 225 (Stubble 758, 768 and
769) are not labeled. Substrate specificity is usually conferred by amino acids at residues 189,
216 and 226 (Stubble residues 732, 760 and 770). Carbon atoms are shown in gray, oxygen in
red, sulfur in yellow and nitrogen in blue. The catalytic serine is boxed. The substrate is shown in
green. Taken from Berg, Tymoczko, and Stryer, 2007.

Several of the mutations found in the 12 sbd alleles analyzed (see Table 8) affect
structures involved in protease activation, folding and substrate binding as discussed above.
Given the importance of proper maintenance of these structures on protease function, these
mutations are likely to have substantial effects on Stubble proteolytic activity. For example,
Glycine 760, which functions as one of the four glycine hinge residues necessary for proper
activation domain folding, is substituted for a serine residue in sbdE(br)228. It has been proposed
that restriction of flexibility around these hinges by amino acid substitution may lead to a
zymogen-like conformation in the active protease (Gombos et al., 2008). The necessity of
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functional glycine hinges for enzymatic activity is exemplified by the finding that substitution of
any of the hinge glycines in blood coagulation-related serine protease factors VII, IX and X leads
to bleeding disorders (Bernardi et al., 1996; Giannelli et al., 1994; Uprichard et al., 2002; Wulff
et al., 2000).
Both sbdE(br)20 and sbdE(br)228 contain mutations in highly conserved residues that directly
interact with the substrate during binding (Huber and Bode, 1978). In the allele sbdE(br)20, serine
758, which is involved in direct binding with the P1 residue of the substrate, is altered to a
phenylalanine. In sbdE(br)228, glycine 760 is altered to a serine residue. Gly760 is involved in
direct binding with the P3 residue of the substrate. Both of these changes are nonconservative. In
the case of S758F, a polar residue is replaced with a nonpolar residue, and a nonpolar residue is
replaced with a polar residue as a result of the G760S mutation. A shift between nonpolar and
polar amino acids in each case could result in misfolding of the substrate binding pocket.
Nonpolar amino acids tend to face the interior of the folded molecule while polar residues tend to
cluster to the surface where interactions with water molecules in the surrounding environment
are maximized. Thus the substitution of Ser758 for phenylalanine in sbdE(br)20 as well as the
substitution of Gly760 for serine in sbdE(br)228 potentially interfere with normal Stubble function
be inhibiting substrate binding and disrupting intramolecular interactions between various
regions of the catalytic domain.
sbdPNR11 contains a point mutation which results in the substitution of aspartic acid 737
for asparagine. Aspartic acid 737 is involved in the formation of the Ile544-Asp737 salt bridge
(Ile16-Asp194 in chymotrypsinogen numbering). This salt bridge stabilizes the folded activation
domain and is necessary for linkage of the catalytic triad with the oxyanion hole during substrate
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binding (see Figure 12). Disruption of this salt bridge due to the substitution of asparagine for
aspartic acid at amino acid 737 is predicted to inhibit proper stabilization of the active molecule
and lead to a zymogen-like conformation with greatly diminished substrate binding capabilities.
The sbd258 mutant allele contains a single amino acid substitution, G755E, in the protease
domain that alters the normal activity of the Stubble protein. Glycine 755 is a highly conserved
residue in a highly conserved region of the protease domain. This glycine residue is located 3
residues amino-terminal to the polypeptide binding site but is not known to be directly involved
in substrate binding. The substitution of a nonpolar, hydrophobic glycine residue for a polar,
hydrophilic glutamic acid residue in such close proximity to the substrate binding pocket could
inhibit proper folding of the substrate binding pocket and thus interfere with the ability of the
Stubble protease to bind and cleave substrates properly.
In addition to the specific mutations found within the various structures of the protease
domain, several sbd alleles contain truncations which remove a portion or the whole of the
protease domain. sbd206 and sbdE(br)448 both contain single point mutations which result in the
change of a glutamine residue for a stop codon. The sbd206 allele contains a nonsense mutation at
residue 445 in the stem of the Stubble protein (see Figure 9). This substitution leads to truncation
of the protein within the stem, completely eliminating the protease domain. The sbdE(br)448 allele
contains a nonsense mutation at residue 714, twenty-four residues N-terminal to the catalytic
triad serine residue in the protease domain (see Figure 9). This substitution results in a truncation
which removes the catalytic serine as well as the substrate binding domain. A third allele, sbd266,
also causes a truncation of the protein, but it does not involve a nonsense mutation. This allele
contains a threonine-to-asparagine amino acid substitution at residue 587 (see Figure 9) which is
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directly followed by an out-of-frame 292-bp deletion. The frameshift results in the addition of 14
incorrect residues onto the modified asparagine before reading into a stop codon. This
deletion/frameshift mutation effectively removes the majority of the protease domain, including
all three residues of the catalytic triad and the substrate binding pocket.
In addition to an amino acid substitution and an out-of-frame deletion, sbd266 also
contains an amino acid substitution within the Stubble stem region. The proline residue at
position 137 is altered to a leucine. This proline residue directly precedes the disulfide-knotted
domain, and a substitution could potentially cause improper folding and disruption of the
flanking disulfide-knotted domain. As this allele also contains a deletion that removes the
majority of the protease domain, it is unclear to what extent the P137L amino acid substitution
contributes to the sbd266 phenotype.
The sbdE(br)623 allele contains a 24-bp deletion in the intron separating exons 10 and 11 in
the proteolytic domain (see Table 8 and Figure 9). The deleted portion of the intron contains the
lariat branch point consensus sequence CTAAT, in which branch formation occurs at the
underlined A (Mount et al., 1992; Figure 15). Splicing events begin with assembly of the
spliceosome onto the pre-mRNA by binding sequences located at the 5’ and 3’ ends of the intron
(reviewed in Graveley, 2004). This assembly is initiated by association of the U1 small nuclear
ribonucleoprotein (snRNP) with the 5’ splice site, the branch-point-binding-protein/SF1 with the
branch point, and the U2 snRNP auxiliary factor (U2AF) with the pyrimidine tract. Stable
association of the U2 snRNP at the branch point and splice-site pairing then occurs upon ATP
hydrolysis. Few mutations of branch point sequences have been identified, but those that have
been found have resulted in cryptic splicing (Rosenthal et al., 1992; Brand et al., 1996; Fujimaru
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et al., 1998), intron retention (Kuivenhoven et al., 1996) and exon skipping (Putman et al., 1997;
Burrows et al., 1998; Hamlington et al., 2000). Therefore, the splicing defect in sbdE(br)623 is
likely to alter the C-terminus of the protease domain. If the intron is retained as a result of
branchpoint deletion, 31 nucleotides would be added between exons 10 and 11. This addition
would cause a frameshift reading into exon 11, resulting in the addition of 51 new amino acids
before reading into a stop codon. Exon 11, which is C-terminal to all members of the catalytic
triad (see Figure 9), contains the substrate binding site as well as the S1 specificity pocket. The
frameshift would disrupt both of these structures and thus result in disruption of normal protease
activity.

Exon 10

IVS 10

Exon 11

GTGAGATGCCGGATAAAGCAAACCTACGAGATATATGCTAATAAACATTTTGCAG

Figure 15. Schematic of the sbdE(br)623 intronic mutation.
Exons 10 and 11 are shown as orange boxes with intron, or intervening sequence (IVS), 10 as a
connecting line. The intronic sequence is expanded below: the deleted 24-bp segment is in blue
and the lariat branch point consensus sequence is underlined.
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The final mutation identified, P662L, is found in the sbdVE3 allele. This proline residue is
very highly conserved across serine proteases and is found in a highly conserved region of the
protease domain. Two residues N-terminal to this residue is cysteine 660, which forms a salt
bridge with cysteine 532 within the stem region. This disulfide bridge tethers the protease
domain to the stem region upon activation cleavage. Altering the proline residue to a lysine could
result in disruption of this disulfide bridge by misfolding the protein such that the thiol groups of
the cysteine residues are no longer able to form a covalent linkage. This would result in shedding
of the protease domain from the protease stem region and the cell surface upon activation
cleavage.
iii.) Apparent sbd regulatory mutations
Of the 12 sbd alleles sequenced, sbd1, sbdE(br)48 and sbdE(br)536 have no changes within the
coding region that would obviously affect protease function. These alleles are therefore
presumed to be regulatory in nature, although this would have to be confirmed with further
experimentation such as steady state RNA or protein level analysis, etc.
Two polymorphisms were found in sbd1 that are not present in the other sbd alleles
analyzed. The first change, 1025C>T, is a synonymous change altering a leucine codon from
CTA to TTA. Neither of these is a preferred leucine codon in Drosophila melanogaster, but the
alteration from CTA to TTA results in a change to the rarest codon for leucine (Codon Usage
Database; http://www.kazusa.or.jp/codon/). The second change, 2812G>A, results in alteration
of the preferred CAG glutamine codon to the less frequently used CAA glutamine codon
(Akashi, 1995). Thus these changes, while silent with respect to amino acid substitution, could
potentially affect translation of the Stubble polypeptide through use of non-preferred codons.
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Adzhubei et al. (1996) suggested that the presence of a rare non-preferred codon in the mRNA
can be associated with mis-folding of the nascent polypeptide. A recent finding by KimchiSarfaty et al. (2007) supports this hypothesis. They showed that the human Mutlidrug Resistance
1 (MDR1) gene containing a single nucleotide silent polymorphism is associated with altered
conformation and substrate specificity of the MDR1 gene product P-glycoprotein. The
polymorphism, which was previously linked to altered function of P-glycoprotein, results in
usage of a rare synonymous codon.
iv.) Future investigations of Stubble mutations identified in these studies
To date, the majority of, if not all, published mutational studies of type II transmembrane
serine proteases have been done in human patients affected by a number of diseases. Such
studies allow researchers to draw associations between mutations in TTSPs and disease, but they
do not allow for direct functional analysis of proteases harboring disease-associated mutations in
an in vivo system. However, taking advantage of the multitude of resources that are available in
Drosophila, we can express a protease containing a mutation of choice and subsequently analyze
the direct effect of that mutation on protease function in vivo.
We plan to use two assays, a leg malformation assay and a bristle defect rescue assay, to
determine the direct effects of a set of specific mutations on Stubble function during epithelial
morphogenesis. Using site-directed mutagenesis, I generated 12 individual mutations (Table 15)
in a full-length wild-type Stubble cDNA and placed them under the control of a heat-shock
promoter in the vector pCaSpeR-hs (Thummel and Pirrotta, 1991). These mutant constructs will
be used to make transgenic animals which, upon exposure to high temperatures, will upregulate
expression of the mutant protein.
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Previously, Bayer et al. (2003) showed that a 1-hr induction of a wild-type hs-Stubble
transgene at 0 hr and 3 hr after pupariation (AP) results in a high percentage of severe leg
malformation in adults and determined that the leg malformation associated with overexpression
of Stubble is specific to a critical period of leg development between 0 and 10 hours AP. These
data provide us with an assay which allows for analysis of protease function in animals
expressing the mutant hs-Stubble transgenes. Staged 0 hr or 3 hr prepupae homozygous for the
mutant hs-Stubble constructs will be exposed to a constant temperature of 37° for 1 hour. If
Stubble activity is retained at significant levels upon introduction of the mutant protein, adult
animals are expected to have an elevated frequency of leg malformation compared to control
animals in which the transgene is not induced. If, on the other hand, the mutation severely
reduces Stubble activity, few malformed adults will be observed. One caveat to the interpretation
of these experiments is that a mutation that causes an increase in Stubble activity will also result
in a high frequency of malformed adults and would therefore be difficult to distinguish from
mutations that do not significantly affect Stubble activity.
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Table 15. Mutant constructs for leg malformation and bristle defect rescue assays
Mutant Constructs
H573R
P137L
G760S
G760R
S549I
S549N
Cys2→Ser
Cys3→Ser
Cys5→Ser
Met1→Leu
Met2→Leu
S49N

Description
Alters histidine 573 to arginine (CAC to CGC)
Alters proline 137 to leucine (CCA to CTA)
Alters glycine 760 to serine (GGC to AGC)
Alters glycine 760 to arginine (GGC to CGC)
Alters serine 549 to isoleucine (AGC to ATC)
Alters serine 549 to asparagine (AGC to AAC)
Alters cysteine 147 to serine (TGC to TCC)
Alters cysteine 153 to serine (TGC to TCC)
Alters cysteine 173 to serine (TGC to TCC)
Alters methionine 1 to leucine (ATG to TTG)
Alters methionine 24 to leucine (ATG to TTG)
Alters serine 49 to asparagine (AGC to AAC)

To confirm interpretations based on the leg malformation assay, a second assay, which
looks for rescue of the sbd bristle phenotype, will be employed. Hammonds and Fristrom (2006)
showed that the recessive bristle phenotype of the mild hypomorphic mutant, sbd2, could be
rescued completely with a wild-type hs-Stubble transgene upon a 1-hr induction at 37° at 27.5 hr
AP. This assay can also be used for analysis of protease function in animals expressing the
mutant hs-Stubble transgenes. For this assay, mutant transgenes will be placed in a homozygous
sbd2 background. The resulting hs-Stubble*/hs-Stubble*; sbd2/sbd2 animals will be staged to 27.5
hr AP, at which point they will be subjected to a 1-hr heat-shock induction at 37°. If the
introduced mutation causes no significant change from the normal level of Stubble activity,
100% of adult animals should exhibit normal bristles (i.e. the short bristle phenotype of sbd2
homozygotes will be rescued). If the mutation reduces Stubble function, incomplete, or no
rescue, of the bristle defect is expected. As with the leg malformation assay, mutations that
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increase Stubble activity cannot be easily distinguished from those with close to normal activity
in this assay. Nevertheless, these assays should provide a useful tool to determine the effect of a
given mutation on proteolytic activity in vivo.
Twelve individual site-directed mutant constructs of the Stubble protease will be tested
for function in the leg malformation and bristle rescue assay systems (Table 15). These
constructs have been designed to answer a variety of questions. For example, the H573R
construct mimics the mutation found in the sbd201 allele that has been attributed by Hammonds
and Fristrom (2006) to the sbd phenotype observed. This construct will allow us to determine
whether the H573R mutation reduces function of the protease in vivo.
The P137L mutation, which affects the proline residue directly preceding the disulfide
knotted domain, was found in the sbd266 allele. This allele also contains a large deletion that
effectively removes the majority of the protease domain. Thus, it is unclear whether the P137L
mutation plays any role in altering the function of the Stubble protease in the sbd266 mutant.
Using a P137L construct will allow us to test whether this mutation, which could potentially
disrupt folding of the disulfide knotted domain, is capable of reducing Stubble function.
Mutation of the human matriptase equivalent of Stubble glycine 760 has been implicated
in autosomal recessive skin disease. Basel-Vanagaite et al. (2007) identified a missense mutation
which alters this glycine residue to an arginine residue (G827R in matriptase) in patients
exhibiting ichthyosis with hypotrichosis (ARIH) syndrome. This mutation has been shown to
result in inactivation of matriptase in an in vitro system (Désilets et al., 2008). The Stubble
equivalent of G827 in matriptase is also mutated in the Stubble mutant allele sbdE(br)228. In
contrast to the G827R mutation in matriptase, Stubble Gly760 is substituted for a serine residue.
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Because the resulting amino acids differ, I have made two mutant Stubble constructs affecting
Stubble Gly760. The first, G760S, mimics the mutation found in sbdE(br)228. The second, G760R,
mimics the mutation found in human ST14, the gene encoding matriptase. These constructs will
allow us to determine whether different types of substitutions at this position affect protease
function differently and, more importantly, to determine in an in vivo system whether the Stubble
G760R equivalent of the human matriptase G827R mutation yields an inactive protease.
The mutation N29I in human trypsinogen, the inactive form of trypsin, has been linked to
pancreatitis (Gorry et al., 1997). In the Stubble protein, the equivalent residue is Ser549. Because
mutation at this non-conserved amino acid position has been linked to disease, I decided to alter
Stubble Ser549 to asparagine and isoleucine. These changes mimic the wild-type residue in
human trypsinogen (N) and the mutant residue in human trypsinogen linked to pancreatitis (I).
The S549N and S549I constructs will allow us to determine whether asparagine can functionally
substitute for serine at position 549 in the Stubble protease, and to determine if isoleucine at this
position reduces in vivo activity, thus lending support to the data linking the N29I mutation to
pancreatitis.
To directly test whether the disulfide knotted domain is necessary for Stubble activity, I
have made three mutant constructs which alter various cysteine residues within the disulfide
knotted domain to serine residues. These changes are based on a previous study in the
Drosophila snake protease in which mutations were introduced into the disulfide knotted domain
of this protease (Smith et al., 1994). The three cysteine residues altered were chosen based on the
fact that each is involved in formation of a separate salt bridge necessary for proper folding of
the disulfide knotted domain. By altering each salt bridge individually, we can assay the
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requirement for the salt bridge on Stubble protease activity. If the disulfide knotted domain is
necessary for Stubble function, disrupting any of the salt bridges is predicted to lead to inactivity.
Two putative start codons are present in the 5’ region of the Stubble protease. Though the
second has a slightly stronger Kozak consensus, the first is generally given as the start site.
Because it is unknown which of these methionine residues is used for the start of translation, I
have made two mutant constructs in which one of the two residues is changed to a leucine
residue. Alteration of the start codon, whether it be the ATG encoding Met1 or the ATG
encoding Met2 (amino acid position 24), should eliminate activity of the Stubble protease unless
the alternate ATG codon can be recruited as the start codon. In the former case, a reduction of
activity would be expected. If both Met codons can be used to initiate translation, no significant
effect on Stubble protease activity is expected.
Finally, the S49N construct targets a putative PKC phosphorylation site in the
cytoplasmic domain. The PKC phosphorylation site is one of three motifs found within the
cytoplasmic domain of the Stubble protease. All three motif types, PKC phosphorylation, cAMP
phosphorylation, and N-myristoylation, have a high probability of occurrence based on the
consensus patterns used for identification. Although mutations affecting the cytoplasmic domain
were not observed in the sequenced alleles, the possibility that this domain is a substrate for a
kinase should be resolved. The introduced mutation alters the serine at position 49 to an
asparagine, thus eliminating the putative PKC phosphorylation site. Therefore, if this domain is
necessary for function, it is likely that alteration of this site will inhibit function of the protease.
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v.) Summary of molecular and genetic analysis of sbd alleles investigated in this study
I was interested to know if there is a correlation between the type of molecular lesion and
the genetic characteristics of the sbd alleles tested. The data obtained from sequencing
experiments, complementation assays and lethal phase analyses are summarized for each sbd
allele in Table 16. At least one trend is apparent within individual datasets. All mutations
resulting in truncation of the protease domain or direct disruption of substrate binding exhibit
predominantly larval lethality with no animals reaching the pupal stage. However, when
considering mutation type, genetic interaction with Rho1 pathway members and lethal phase
together, no obvious correlations emerge.
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Table 16. Summary of genetic data for the mutant sbd alleles
Allele

Strength of interaction with

Molecular Lesion
Rho1720

Rho1J3.8

Rho1E3.10

Lethal Phase

Rho1k02107

zipEbr

sbd1

Putative Regulatory

None

None

None

None

Weak

Broad Spectrum

sbd206

Q446X

None

None

Weak

Weak

Moderate

Larval

sbd258

G755E

None

None

None

None

Moderate

Embryonic

sbd266

P137L; T587N followed by 292-bpΔ
and frameshift + 14aa then stop codon

None

None

None

None

Weak

Larval

sbdE(br)20

S758F

None

None

None

Weak

Weak

Larval

Putative Regulatory

None

None

None

None

Weak

Larval w/9% pupariating

sbdE(br)228

G760S

None

None

None

None

Weak

Pupal w/34% larval

sbdE(br)448

Q714X

None

None

None

None

Weak

Larval

sbdE(br)536

sbd

E(br)48

Putative Regulatory

None

Weak

Weak

Weak

Weak

Larval

sbd

E(br)623

IVS10:Δlariat consensus

None

Weak

None

None

Weak

Larval w/15% pupariating

sbd

PNRII

D737N

None

None

None

None

Moderate

Larval

P662L

None

None

None

None

Larval w/29% embryonic

sbdVE3

None
720

1

Strength of interaction is defined for the doubly heterozygous class, i.e. Rho1 /+; sbd /+, as none for a malformation rate of
less than 5%, weak for a malformation rate of 5%-24%, moderate for a malformation rate of 25%-49% and strong for a
malformation rate greater than 50%.
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GPCRs and other candidate regulators of epithelial morphogenesis
Four genomic regions exhibiting genetic interaction with the Stubble protease in control
of epithelial morphogenesis have been identified through the primary screen of the non-odorant,
non-gustatory G protein-coupled receptors in the Drosophila genome. Combined, these regions
uncover at least 123 genes including 8 GPCRs, as well as a number of other genes that could
potentially play a cooperative role with Stubble and the Rho1 pathway in regulation of actin
cytoskeletal dynamics.
A total of 21 annotated genes are contained within the region uncovered by
Df(2L)Exel7027 (see Appendix B), including the GPCR gonadotropin-releasing hormone
receptor (GRHR). The Drosophila GRHR is evolutionarily related to the mammalian GRHR,
which is involved in various aspects of reproduction (Hauser et al., 1998). Drosophila
microarray data from whole animals suggests that GRHR is most highly expressed throughout
larval development and during the first 8 hours of metamorphosis (Arbeitman et al., 2002). This
expression pattern overlaps that of Stubble and corresponds to the developmental period during
which the leg discs undergo morphogenesis.
The genomic region uncovered by Df(2R)Exel6068 contains 16 annotated genes (see
Appendix B). Two of these, 5-HT1A and 5-HT1B, are G protein-coupled serotonin receptors
known to be involved in regulation of sleep (Yuan et al., 2006) and circadian rhythms (Yuan et
al., 2005), respectively. Both receptors are expressed during late embryogenesis in the central
nervous system (Saudou et al., 1992), but complete expression profiles have not been
determined.
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A third deficiency which shows very strong interaction with Sb63b is Df(3L)Exel6084.
This deficiency deletes genomic region 61B2-61C1, which completely removes 43 annotated
genes (see Appendix B), including methuselah-like (mthl) 9, mthl10 and mthl14. These are three
structurally related GPCRs potentially involved in aging and stress response (Brody and
Cravchik, 2000). Other interesting genes uncovered by Df(3L)Exel6084 are RhoGEF3 and the
serine-type endopeptidase inhibitors Kaz1-ORFA and Kaz1-ORFB. Also deleted is Enhancer of
bithorax (E(bx)), an ATP-dependent chromatin remodeling complex that must bind the Ecdysone
Receptor (EcR) in order for ecdysone-responsive genes to be expressed (Badenhorst et al.,2005).
A secondary screen using overlapping deletions to further identify the gene(s) within
Df(3L)Exel6084 which interact with the Stubble protease was also performed (see Table 13 and
Figure 10). This screen identified two much smaller regions uncovered by Df(3L)BSC128 and
Df(3L)Exel9057 which split the larger Df(3L)Exel6084 into two separate interacting regions.
Df(3L)BSC128 has molecular breakpoints 184799-212410 on chromosome 3L. This region
uncovers the entire coding sequence of 7 genes and partially uncovers 2 additional genes (Table
17). The GPCR mthl14 is just outside the right breakpoint of the BSC128 deficiency and could
well be within the deleted region if the right breakpoint of Df(3L)BSC128 is inaccurate.
Df(3L)Exel9057 has molecular breakpoints 306168-319594 on chromosome 3L, a region which
contains only 2 genes, four wheel drive (fwd) and CG34264, and fully deletes the coding domain
of each (Table 17). The GPCRs mthl9 and mthl10 are not deleted by this deficiency.
None of the genes lying within the breakpoints of Df(3L)BSC128 or Df(3L)Exel9057
stand out as obvious candidates to interact with Stubble in control of epithelial morphogenesis. It
is possible that one of these deficiencies removes the regulatory region of a more likely
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candidate located outside of the deficiency region. Alternatively, the given breakpoints for these
deficiencies may be inaccurate. In the latter case, the list of genes uncovered by Df(3L)BSC128
and Df(3L)Exel9057, as presented in Table 17, may not be comprehensive.
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Table 17. Genes uncovered by Df(3L)BSC128 and Df(3L)Exel9057
Df(3L)BSC128
Gene

Molecular Position

Molecular Function

Mitochondrial carrier homolog 1 (Mtch)

184,635-186,317

transmembrane transporter activity; binding

rhinoceros (rno)

188,549-198,587

DNA binding; protein binding; zinc ion binding

mrityu (mri)

200,180-202,165

glycerol kinase activity; protein binding; voltage-gated potassium
channel activity

Glycerol kinase (Gyk)

202,094-205,819

glycerol kinase activity

Nitrilase and fragile histidine triad fusion protein
(NitFhit)

203,699-205,311

bis(5'-adenosyl)-triphosphatase activity; hydrolase activity, acting
on carbon-nitrogen (but not peptide) bonds; nitrilase activity

CG13876

206,192-207,112

amine oxidase activity; quinone binding; copper ion binding

CG7028

207,884-211,462

protein kinase activity; protein serine/threonine kinase activity;
ATP binding

thoc7

211,636..212,687

unknown

CG16940

212,275..216,483

exoribonuclease II activity; RNA binding

methuselah-like 14 (mthl14)

247,495-250,314

G protein-coupled receptor activity

Df(3L)Exel9057
four wheel drive (fwd)

306,207-319,880

1-phosphatidylinositol 5-kinase activity

CG34264

317,208-317,621

unknown

methuselah-like 9 (mthl9)

329,820-332,306

G protein-coupled receptor activity

methuselah-like 10 (mthl10)

333,475-336,682

G protein-coupled receptor activity

GPCRs uncovered by Df(3L)Exel6084 are highlighted in blue. None of these GPCRs are uncovered by Df(3L)BSC128 or
Df(3L)Exel9057, but they are listed to show their proximity to these deficiencies.
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Finally, the genomic region uncovered by Df(3R)red-P52 contains at least 43 annotated
genes (see Appendix B). These include two GPCRs, CG9918 and Dopamine Receptor (DopR).
Interestingly, Srivastava et al. (2005) have recently shown that DopR functions as a cell-surface
GPCR which may be responsible for some of the rapid actions of ecdysteroids during
development. It has become apparent that the rapid action of ecdysteroids, such as ecdysone, is
mediated by mechanisms that alter the levels of secondary messengers which in turn may be
mediated by the activation of GPCRs. The Drosophila DopR protein is activated by dopamine to
increase cAMP levels and activate the phosphoinositide 3-kinase pathway. However, the effects
of dopamine can be inhibited by the binding of ecdysone to the receptor. Once bound, ecdysone
couples the receptor to rapid activation of the mitogen-activated protein kinase pathway.
Additional genes uncovered by Df(3R)red-P52 are CG31326, CG9649, Sp212 and
CG9631, a cluster of four serine-type endopeptidases. It has been suggested that TTSPs may play
a general role as initiators of protease cascades. This is supported by the fact that certain TTSPs,
such as matriptase, have been shown to undergo autoactivation in vitro (Oberst et al., 2003;
Takeuchi et al., 1999). Additionally, all TTSP family members exhibit a strong preference for
substrates containing an arginine or lysine at their cleavage sites, and have these residues at their
own cleavage sites suggesting that they may be capable of autoactivation. More support for this
hypothesis is provided by the discovery that matriptase can activate pro-urokinase plasminogen
activator (pro-uPA) bound to urokinase plasminogen activator receptor (uPAR) thus activating
the plasminogen cascade (Kilpatrick et al., 2006). Interestingly, mutant alleles of Stubble interact
with Notopleural deficiencies which also uncover a cluster of serine proteases (Ruggiero, 2006).
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Broader impacts
Misexpression of TTSPs has been implicated in a number of pathologies, thus
understanding how they function is of great importance. Using Stubble as a model in which to
study the functional mechanism of TTSPs presents the possibility of defining how extracellular
hormonal hierarchies, TTSPs and intracellular signaling pathways interact in vivo. Such a model
of interaction could then be applied toward the understanding of similar interactions in other
systems. The results of the studies presented here help to bring us a step closer to understanding
the mechanistic role of the Stubble protease in epithelial development, and thus to understanding
the mechanism of action of the TTSP family. Through sequence analysis of twelve mutant alleles
of Stubble, the protease domain was identified as essential for proper protease function. Though
only the protease domain has been clearly identified as essential, the remaining conserved
domains cannot be ruled out as necessary components of the functional protein. Further studies,
such as the leg malformation and bristle defect assays using transgenic animals carrying
mutations in the remaining domains, are necessary to determine the contribution of these
domains to Stubble function. In addition to providing a method with which to test functional
necessity of conserved domains, the leg malformation and bristle rescue assays provide us with a
system in which to test the in vivo effects of various mutations, including those found in human
TTSPs implicated in disease, on protease function. Thus, this assay system could prove to be an
extremely important tool for providing direct evidence that disease-associated mutations are
capable of reducing or eliminating protease function.
Another important step in defining the mechanism of action of the TTSP family is the
identification of TTSP substrates. Using a genetic interaction screen focusing on a subset of
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GPCRs, I have identified four genomic regions which show significant interactions with Stubble
mutants. Contained within these regions are a number of genes, including 8 GPCRs, which could
serve as a link between Stubble and the Rho1 pathway or alternatively as Stubble targets in an
independent pathway which regulates epithelial development. To establish a clearer picture of
the types of targets utilized by TTSPs to function in development and homeostasis, further
studies are necessary to identify their direct substrates in vivo.
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APPENDIX A: GPCR MUTATIONS AND DEFICIENCIES TESTED FOR
INTERACTION WITH SB63B
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% malformation with Sb63b

Stock #

Deficiency

GPCRs Affected

BL7700
BL13583
BL9299
BL13875
BL17007
BL5974
BL12523
BL9169
BL8956
BL7708
BL7710
BL945
BL10089
BL9625
BL947
BL13934
BL903
BL11291
BL21192
BL15318
BL8954
BL5271
BL18685
BL6217
BL22030
BL7762
BL7761
BL7764
BL13429
BL14884
BL9351
BL3277
BL16815
BL1567
BL7500
BL9185
BL20304
BL11320
BL7801
BL7817
BL7514

Df(1)Exel6223
P{y+w+}fz3KG04032
Df(1)ED6565
P{y+w+}KG05130
P{EP}moodyEP1529
Df(1)X12
P{w+mGT=GT1}BG00979
Df(1)ED6712
Df(1)ED6727
Df(1)Exel6234
Df(1)Exel6236
Df(1)C149
P{w+mC=EP}Tre1EP496
Df(1)ED6878
Df(1)HA32
P{y+w+}KG02367
Df(1)V-L3
P{w+mC}CG2061EP1537
P{w+mCy+}mthl1Ey16157
P{w+mCy+}mthl1EY00861
Df(1)ED7374
Df(1)D15
PBac{w+mC}CG7536f03720
Df(1)RR79

fz3
fz3
CG4313
CG4313
CG4313
CG13758
CG13758
AlstR
CG6986
CG16752
Tre1
Tre1
Tre1
CG12796
fz4
fz4
CG2061
CG2061
mthl1
mthl1
CG4875
CG4875
CG7536
CG7536
CG7536
CCKLR-17D1
CCKLR-17D1
CCKLR-17D1 and 17D3
CCKLR-17D3
CCKLR-17D3
D2R
smo
CG9643
CG9643
CG31645
CG13995
GRHR
GRHR
GRHR
CG31720
Rh5

P{Mae-UAS.6.11}CG7536GE01344

Df(1)Exel9051
Df(1)Exel7463
Df(1)Exel7464
P{y+w+}KG01373
P{y+w+}KG01171
Df(1)ED7635
smo3
P{w+mCy+}CG9643EY07345
Df(2L)JS17
Df(2L)Exel6014
Df(2L)ED343
P{w+mCy+}GRHREY11371
PBac{PB}GRHRc03956
Df(2L)Exel7027
Df(2L)Exel8024
Df(2L)Exel6031
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8.3
0.5
not enough data
0
3.8
0
0
0
0
0
4.4
0
3.2
0
10.3
1.6
0
2.1
13.8
0
2.4
5.9
10.5
0
5.6
0.5
0
11.4
1.1
4.4
4.5
0
1.4
4.4
27.5
0
4.8
8.6
57.1
10.8
16.7

Stock #

Deficiency

GPCRs Affected

BL6080
BL3589
BL3590
BL6965
BL10919
BL3212
BL7831
BL7527
BL9683
BL21572
BL7862
BL7863
BL21398
BL9410
BL6072
BL6969
BL6967
BL6969
BL7541
BL9596
BL16906
BL5574
BL10836
BL7550
BL7998
BL7912
BL1473
BL7914
BL18327
BL8046
BL2577
BL7563
BL17137
BL18405
BL8048
BL2400
BL8096
BL7571
BL7584
BL17948
BL6940

Df(2L)noc11
rk1
rk4
rk81f2
P{w+tARry+t7.2AR=wAR}rk11P
Df(2L)do1
Df(2L)Exel7063
Df(2L)Exel6045
Df(2R)ED1484
P{y+t7.7w+mC}mxrDG17503
Df(2R)Exel7096
Df(2R)Exel8047
P{w+mCy+mDint}CirlEY12930
Df(2R)BSC132
stan81f1
stan192
stanfz3
stan192
Df(2R)Exel6059
Df(2R)BSC161
P{EPgy2}mthl3EY08706
P{w+mC=lacW}mthl3K10408
P{w+mC}l(2)k01209K08901a
Df(2R)Exel6068
Df(2R)Exel7166
Df(2R)Exel7184
In(2LR)Px4
Df(2R)Exel7185
PBac{w+mC}CG13579f00432
Df(3L)ED4079
Df(3L)emc-E12
Df(3L)Exel6048
P{w+mC=EP}EP3542
PBac{w+mC}mthl10f01047
Df(3L)ED4177
Df(3L)R-G7
Df(3L)ED4287
Df(3L)Exel6092
Df(3L)Exel6105
PBac{w+mC=RB}mthl2e01373
Df(3L)XAS96

rk
rk
rk
rk
rk
CG4168
kek3
CG10481
CG14593
mXr
mXr
Cirl
Cirl
CG30340
stan
stan
stan
stan
CG13229
mthl4
mthl3
mthl3
mthl3
5-HT1A, 5-HT1B
CG3216
CG13575
mAcR-60C
CG13579
CG13579
mthl8
mthl8,14, 9,10, mth
mthl14, mthl9, mthl10
mthl9
mthl10
mth
DmsR-2
DmsR-2, DmsR-1
FR
mthl2
mthl2
CG10483
94
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2.8
4.4
not enough data
4.7
0
0
21.6
13.8
2.4
1.5
4.1
18.8
0.7
22.9
0.8
11.1
0
8.1
3.8
9.3
1.2
1.9
2.4
34.5
7.4
7.7
2.7
10.5
24.1
0
0
98.0
11.0
17.1
0
9.1
2.7
0
26.0
30.0
4.2

% malformation with Sb63b

Stock #

Deficiency

GPCRs Affected

BL19366
BL1420
BL7929
BL7591
BL997
BL7593
BL19575
BL2611
BL7595
BL2612
BL8070
BL5408
BL3124
BL1676
BL7601
BL12512
BL15624
BL7937
BL18260
BL8100
BL7613
BL18622
BL6754
BL5126
BL8088
BL8101
BL9700
BL10268
BL1559
BL19367
BL7628
BL9215
BL8095
BL18486
BL7974
BL18563
BL18464
BL1900
BL19491
BL7977
BL2057

PBac{}CG10483PL00048
Df(3L)pbl-X1
Df(3L)Exel8104
Df(3L)Exel6112
Df(3L)AC1
Df(3L)Exel6114
PBac{}CG33696PL00631
Df(3L)vin5
Df(3L)Exel6116
Df(3L)vin7
Df(3L)ED4483
l(3)SG111fz1
Df(3L)fz-Gf3P
fz1
Df(3R)Exel6174
P{w+mGT=GT1}fzBG00824
P{w+mCy+}fzEY03114
Df(3L)Exel9004
PBac{w+mC=RB}Rh4e04456
Df(3L)ED4710
Df(3L)Exel6134
PBac{w+mC}AlCR2f0316
Df(3L)fz2
Df(3L)XS533
Df(3L)ED4858
Df(3L)ED4978
Df(3L)BSC223
P{hsneo}TyrRneo30
Df(3R)110
PBac{}5-HT2PL00052
Df(3R)Exel6149
Df(3R)ED5495
Df(3R)ED5558
PBac{w+mC}CG8784f01901
Df(3R)Exel8158
PBac{w+mC}CG8795f02573
PBac{w+mC}CG9918f01726
Df(3R)red-P52
PBac{}DopRPL00420
Df(3R)Exel7321
Rh61

CG10483
mthl6
mthl6
mthl7
CG6749
CG33696
CG33696
Rh7
Rh7
GRHRII
GRHRII
fz
fz
fz
fz
fz
fz
Rh4
Rh4
CG7497
AlCR2
AlCR2
fz2
NPFR76F
NPFR76F
capaR
TyrR
TyrR
5-HT2
5-HT2
CG8007
mthl11
mthl5
CG8784
CG8784, CG8795, mthl12
CG8795
CG9918
CG9918, DopR
DopR
DopR
Rh6
95

3.5
0
5.0
4.5
7.5
3.7
0
7.4
21.4
0
0
41.7
6.7
0
7.7
0
3.8
0
16.4
0
5.9
15.6
0
8.1
0
0
5.3
3.7
3.5
0
1.7
0
0
19.4
5.5
30.9
17.1
87.5
15.3
11.9
0

Stock #

Deficiency

GPCRs Affected

BL7653
BL7981
BL9207
BL18659
BL7660
BL19331
BL3012
BL1861
BL2103
BL5701
BL9479
BL9485
BL16202
BL7681
BL5601
BL9500
BL7683
BL10400
BL7684
BL7688
BL7692
BL18848
BL5415
BL18199
BL7919
BL18120
BL7084
BL9579

Df(3R)Exel6174
Df(3R)Exel8162
Df(3R)ED5785
PBac{WH}CG18208f03483
Df(3R)Exel6181
P{w+mC=XP}cryd10630
Df(3R)D1-BX12
ninaE8
ninaE7
ninaE17
Df(3R)ED6027
Df(3R)ED10838
PBac{w+mC=5HPw+}B322
Df(3R)Exel6202
Df(3R)Espl3
Df(3R)BSC140
Df(3R)Exel6204
PBac{w+mC=PB}NepYrc01146
Df(3R)Exel6205
Df(3R)Exel6210
Df(3R)Exel6214
PBac{w+mC }5-HT7f05214
Df(3R)t11-e
PBac{w+mC}CG11318e03837
Df(3R)Exel7379
PBac{w+mC}CG15556e03142
Df(4)O2
Df(4)ED6380

Rh6
CG31183
Fsh
CG18208
CG18208, Rh2
cry
cry, ninaE, Rh3
ninaE
ninaE
ninaE
Rh3
ETHR, SIFR
SIFR
CG11910
boss
boss
CG12290
NepYr
NepYr
AR-2
AdoR
5-HT7
5-HT7
CG11318
CG11318, CG15556
CG15556
Glu-RA
Glu-RA
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1.6
5.0
0
24.6
23.6
0
5.4
2.7
2.4
7.7
0
3.1
2.3
6.9
4.5
6.1
4.8
0
20.0
lethal - artifact
10.4
18.0
3.3
4.1
2.4
8.2
8.6
0

APPENDIX B: GENES UNCOVERED BY DF(2L)EXEL7027,
DF(2R)EXEL6068, DF(3L)EXEL6084 AND DF(3R)RED-P52
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Df(2L)Exel7027
Gene
CG9232
Serpin-27A
CG34310
cortex
CG11329
Nhe3
CG11327
Thrombospondin
Gonadotropin-releasing
hormone receptor
CG11188
homer
Liprin-α
CG11201
CG11323
CG11221
snoRNA:Me28S-G2743
CG31910
CG11322
CG11321
CG17378
nervana 1

Molecular Function
UDP-glucose:hexose-1-phosphate uridylyltransferase activity; metal
ion binding
serine-type endopeptidase inhibitor activity; enzyme inhibitor activity
unknown
unknown
unknown
sodium:hydrogen antiporter activity; solute:hydrogen antiporter
activity
unknown
calcium ion binding
neuropeptide receptor activity; G-protein coupled receptor activity;
peptide receptor activity; gonadotropin-releasing hormone receptor
activity; rhodopsin-like receptor activity
unknown
unknown
unknown
tubulin-tyrosine ligase activity
tubulin-tyrosine ligase activity
protein kinase activity; protein serine/threonine kinase activity; ATP
binding
unknown
unknown
unknown
protein binding; zinc ion binding
unknown
sodium:potassium-exchanging ATPase activity; hydrolase activity,
acting on acid anhydrides, catalyzing transmembrane movement of
substances; cation transmembrane transporter activity
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Df(2R)Exel6068
Gene
serrano
proliferation disrupter
CG15107
Topoisomerase Iinteracting protein
CG18605
CG15105
Serotonin receptor 1B
CG30126
CG15115
CG15116
CG15109
Serotonin receptor 1A
CG30125
CG15117
brother of tout-velu
CG15111

Df(3L)Exel6084
Gene
CG13875
CG34140
MAP kinase-specific
phosphatase
Mitochondrial carrier
homolog 1
rhinoceros
mrityu
Glycerol kinase
Nitrilase and fragile
histidine triad fusion
protein
CG13876

Molecular Function
unknown
chromatin binding
unknown
ubiquitin-protein ligase activity; DNA topoisomerase I binding; zinc
ion binding
unknown
protein binding; zinc ion binding
5-HT1 receptor activity; serotonin receptor activity; G-protein
coupled serotonin receptor activity; amine receptor activity
unknown
unknown
glutathione peroxidase activity
unknown
serotonin receptor activity; 5-HT1 receptor activity; G-protein
coupled serotonin receptor activity; amine receptor activity
unknown
beta-glucuronidase activity; cation binding
heparan sulfate N-acetylglucosaminyltransferase activity;
acetylglucosaminyltransferase activity; glucuronyl-galactosylproteoglycan 4-alpha-N-acetylglucosaminyltransferase activity
unknown

Molecular Function
calcium ion binding
unknown
MAP kinase tyrosine/serine/threonine phosphatase activity;
phosphoprotein phosphatase activity; protein tyrosine phosphatase
activity
transmembrane transporter activity; binding
DNA binding; protein binding; zinc ion binding
glycerol kinase activity; protein binding; voltage-gated potassium
channel activity
glycerol kinase activity
bis(5'-adenosyl)-triphosphatase activity; hydrolase activity, acting on
carbon-nitrogen (but not peptide) bonds; nitrilase activity
amine oxidase activity; quinone binding; copper ion binding
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Gene
CG7028
thoc7
CG16940
Kaz1-ORFA
Kaz1-ORFB
pyrexia
CG13877
CG16971
CG33229
CR32477
CG34454
CG34453
Enhancer of bithorax
methuselah-like 14
DISCO Interacting
Protein 2
CG13879
Tudor-SN
snoRNA:Ψ18S-996
mitochondrial ribosomal
protein L17
CG34263
miple
miple2
CG32845
tiny tim 2
CG13881
CG13882
CG13883
RhoGEF3
four wheel drive
CG34264
CG32344
CG32343
methuselah-like 9
methuselah-like 10

Molecular Function
protein kinase activity; protein serine/threonine kinase activity; ATP
binding
unknown
exoribonuclease II activity; RNA binding
serine-type endopeptidase inhibitor activity
serine-type endopeptidase inhibitor activity
calcium channel activity; cation channel activity
unknown
unknown
unknown
unknown
serine-type endopeptidase inhibitor activity
unknown
ligand-dependent nuclear receptor binding; zinc ion binding
G-protein coupled receptor activity
protein binding; catalytic activity; transcription factor binding
unknown
transcription coactivator activity; nuclease activity; nucleic acid
binding
unknown
structural constituent of ribosome
unknown
growth factor activity
growth factor activity
isomerase activity; protein binding
unknown
unknown
unknown
unknown
Rho guanyl-nucleotide exchange factor activity; signal transducer
activity
1-phosphatidylinositol 4-kinase activity
unknown
helicase activity; ATP-dependent RNA helicase activity; ATP
binding; RNA binding
transcription factor activity
G-protein coupled receptor activity
G-protein coupled receptor activity
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Df(3R)red-P52
Gene
Origin recognition
complex subunit 2
roadkill
Cyp6d5
CG3061
CG9922
transfer RNA:ser2b:88A
forkhead box, sub-group
O
CG3153
CG14358
CG9920
CG9918
CG12402
Odorant receptor 88a
CG14357
Kif19A
Abelson Interacting
Protein
twinfilin
upstream of RpII140
RNA polymerase II
140kD subunit
CG14356
CG14355
CG14359
CG9722
CG31533
CG31327
CG3199
Dopamine receptor
CG9649
CG31326
CG33109
CG33329
CG9631
CG9624

Molecular Function
DNA binding
protein binding
electron carrier activity; heme binding; iron ion binding;
monooxygenase activity
unfolded protein binding; heat shock protein binding
unknown
triplet codon-amino acid adaptor activity
transcription factor activity; sequence-specific DNA binding
unknown
unknown
unfolded protein binding; ATP binding
G-protein coupled receptor activity; growth hormone-releasing
hormone receptor activity; neuropeptide receptor activity
protein binding
olfactory receptor activity; odorant binding
unknown
microtubule motor activity; ATP binding
signal transducer activity; protein binding
actin binding; protein-tyrosine kinase activity
protein transporter activity
DNA-directed RNA polymerase activity; DNA binding
unknown
unknown
unknown
receptor binding
unknown
unknown
unknown
dopamine receptor activity; dopamine D1 receptor-like receptor
activity; G-protein coupled receptor activity
elastase activity; serine-type endopeptidase activity
serine-type endopeptidase activity
unknown
serine-type endopeptidase activity
elastase activity; serine-type endopeptidase activity
unknown
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Gene
CG9616
Methionyl-tRNA
synthetase
CG14840
CG14841
CG14839
trithorax
CG12207
CG3259
suppressor of Hairy
wing
RNA polymerase II
15kD subunit

Molecular Function
unknown
methionine-tRNA ligase activity; ATP binding
unknown
unknown
unknown
DNA binding; histone lysine N-methyltransferase activity (H3-K4
specific); sequence-specific DNA binding; protein binding; zinc ion
binding; transcription factor activity
unknown
unknown
DNA binding; transcription regulator activity; protein binding; zinc
ion binding
DNA-directed RNA polymerase activity; DNA binding; zinc ion
binding; transcription regulator activity
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